# **A sum of its parts: A systematic review evaluating**

# <sup>2</sup> biopsychosocial and behavioral determinants of

# **3 perinatal depression**

- 4 Kayla D. Longoria<sup>1\*</sup>, Tien C. Nguyen<sup>2,3</sup>, Oscar Franco-Rocha<sup>1</sup>, Sarina R. Garcia<sup>2</sup>, Kimberly A. Lewis<sup>1,4</sup>,
- 5 Sreya Gandra<sup>2,5</sup>, Frances Cates<sup>5</sup>, Michelle L. Wright<sup>1,6</sup>
- 6 <sup>1</sup> School of Nursing, University of Texas at Austin, Austin, Texas, USA
- 7 <sup>2</sup> College of Natural Sciences, University of Texas at Austin, Austin, Texas, USA
- 8 <sup>3</sup> University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
- 9 <sup>4</sup> Department of Physiological Nursing, School of Nursing, University of California, San Francisco
- 10 <sup>5</sup> College of Liberal Arts, University of Texas at Austin, Austin, Texas, USA
- 11 <sup>6</sup> Department of Women's Health, Dell Medical School at The University of Texas at Austin, Austin, Texas, USA
- 12 \* Corresponding author
- 13 Email: <u>kdlongoria@utexas.edu</u>
- 14
- 15 Author roles: KDL: conceptualization, project administration, methodology, data curation, formal analysis, resources,

16 writing – original draft preparation. TCN, OFR: data curation, visualization, writing – review and editing SRG, KAL,

17 MLW: data curation, writing – review and editing SG: writing – review and editing FC: writing – review and editing

- 19
- 20
- 1

# 21 Abstract

Introduction Depression is one of the most common yet underdiagnosed perinatal complications and 22 23 our understanding of the pathophysiology remains limited. Though perinatal depression is considered to have a multifactorial etiology, integrative approaches to investigation are minimal. This review takes an 24 25 integrative approach to systematically evaluate determinants and potential interactions among 26 determinants of perinatal depression across four domains (i.e., biological, behavioral, environmental, social) and appraise the quality of methods applied. Methods Four databases (i.e., PubMed, CINAHL, 27 APA PsycInfo, and Web of Science) were systematically searched to identify studies examining 28 determinants of perinatal depression in adult perinatal persons (> 18 years). Articles were excluded if the 29 outcomes were not focused on perinatal persons and depression or depression symptoms, the evaluation 30 31 of depression was specific to a discrete facet of the perinatal period with probable psychological consequences (e.g., abortion, fetal/infant loss, adoption), or was considered grey literature. The Critical 32 Appraisal Skills Programme and AXIS tools were used to guide and standardize quality appraisal 33 34 assessments and determine the level of risk of bias. Results Of the 454 articles identified, 25 articles were included for final review. A total of 14 categories of determinants were investigated: biological (5), 35 behavioral (4), social and environmental (5). Though only 28% of studies simultaneously considered 36 determinants under more than one domain, a pattern of interactions with the tryptophan pathway 37 emerged when determinants across domains were aggregated. Concerns for risk of bias were noted or 38 were unclear for three types of bias: 13 (52%) selection bias, 3 (12%) recall bias, and 24 (96%) 39 measurement bias. **Conclusions** Future research is needed to explore interactions among determinants 40 and the tryptophan pathway; to strengthen the methods applied to this area of inquiry; and to generate 41 42 evidence for best practices in reporting, selecting, and applying methods for measuring determinants and perinatal depression. 43

# 44 Introduction

The leading underlying cause of perinatal death is mental health conditions [1]. Depression is 45 46 one of the most common conditions to occur perinatally as it impacts every one in five perinatal persons [2, 3]. Perinatal depression denotes the manifestation of affective, somatic, and/or cognitive symptoms, 47 ranging in severity, that can occur at any time point in the perinatal period (i.e., conception-12 months 48 postpartum) and impairs one's ability to complete daily activities [2–4]. While impairment in 49 functioning is already of concern due to the increased physiological, psychological, and financial 50 demands generated by this life-stage, distal outcomes (i.e., suicide, opioid use disorder) continue to 51 contribute to the alarmingly unabated maternal mortality rates in the US where 80% of these deaths are 52 53 considered preventable [1, 5, 6]. For instance, suicide, a leading cause of maternal mortality, has tripled 54 over the last decade and accounts for  $\sim 20\%$  of perinatal deaths [6, 7], whereas opioid use disorder accounts for one of the most frequent causes of accidental death [1, 5, 8]. Yet, depression remains the 55 most underdiagnosed perinatal complication in the US [2] suggesting advancements in our 56 57 understanding of the risk for and development of the condition requires timely attention and response. The heterogeneous nature of depression symptoms coupled with the stark overlap of "normal" 58 59 pregnancy symptoms make early detection and intervention difficult. Therefore, the prevalence of perinatal depression is likely underrepresented in part due to the lack of diagnostic expertise in the 60 61 clinicians who are most likely to interact with at-risk individuals, high variability in existing screening 62 practices, and underreporting of symptoms due to perceived stigma [9–11]. Still, 10-20% of perinatal persons are reported to experience depression [3, 12–14]. 63

A majority of research on the etiology of perinatal depression has attempted to dissect it into two
broad camps (i.e., internal factors, external factors) [13]. Investigations are further reduced and often

66 limited to factors respective to a single domain (e.g., biological, behavioral, social, environmental) [12, 13, 15–17]. Evidence suggests interactions among external factors and biological factors can contribute 67 to the onset of pathology [18]. For instance, lower levels of education, income, and occupation status 68 have been associated with elevations in inflammatory markers, chronic disease states, and metabolic 69 dysregulation [19]. Yet, the factors most commonly explored in relation to perinatal depression are 70 71 largely external (e.g., social, environmental, behavioral), such as, social determinants of health, personal or family history of a psychiatric condition, low socioeconomic status (SES), stress, poor social support, 72 intimate partner violence (intimate partner violence), and multiparity [12, 20, 21]. Due to the limited 73 74 understanding of biological factors that may contribute to depression in perinatal populations, biological theories of depression (i.e., immune response, inflammation, tryptophan metabolism) in the general 75 population may be useful in informing initial directions for investigations including biological factors in 76 77 perinatal specific depression [19, 22-25].

Since perinatal depression is considered to have a multifactorial etiology, siloed approaches to 78 investigation may inadvertently omit significant findings related to interactions among factors from 79 differing domains that can advance our understanding of risk and onset. In an era of team science, 80 81 integrative approaches to investigation are not only feasible but desirable to address some of the world's 82 most complex health problems, like perinatal depression. This review aggregates existing literature across various scientific domains and uncovers novel interactions that warrant further investigations into 83 84 the etiology and risk for this complex condition. Advancements in knowledge of distinct determinants 85 and interactions will not only improve our ability to detect existing symptoms but will also progress our aptitude for determining risk status and implementing risk mitigation strategies [10]. Therefore, the 86 purpose of this review is to take an integrative approach to systematically evaluate a) what social, 87 environmental, behavioral, and biological determinants (i.e., immune response, inflammation, 88

tryptophan metabolism) have demonstrated a relationship with perinatal depression b) how such

90 determinants effect perinatal depression, and c) the quality of the methods used in the included studies.

# 91 Methods

## 92 Search Strategy

93 The literature search took place in December 2022. The following databases were searched for articles that encompassed all or some of the specified determinants: PubMed, CINAHL, APA PsycInfo, 94 and Web of Science. The following search terms were used across all databases in the Title/Abstract 95 field: (depression or depressive or mdd or major depressive disorder or clinical depression or unipolar 96 97 depression) AND (social or environmental or behavioral) AND (determinants or characteristics or factors) AND (tryptophan or serotonin or kynurenine or immunology or immune response or immune 98 system or inflammation or inflammatory response or cytokines) AND (metabolites or metabolomics or 99 metabolism) AND (pregnan\* or prenatal or perinatal or antenatal or postpartum or postnatal or matern\* 100 101 or peripartum or intrapartum).

The study selection process was guided by the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) methodology [26]. Search results and duplicates were managed using the open-source reference management software Rayyan [27]. Microsoft Excel was used as a screening and data extraction tool to organize articles among the six authors (KDL, MLW, SG, TCN, KL, OFR), and allowed the primary author to successively cross-check articles screened to confirm eligibility decisions before proceeding to full-text review and quality appraisal.

## **Inclusion and Exclusion Criteria**

109	Articles from any date were included if they focused on a timeframe within the perinatal period
110	(i.e., conception-12 months postpartum), had participants that were 18 years or older, were available in
111	the English language, investigated factors that belonged to at least one of the four domains (i.e.,
112	biological, behavioral, environmental, social), and had an outcome of depression or depression
113	symptoms. We define the four domains as follows: 1) biological: individual features unique to a person
114	that have a biological basis (e.g., genetics, brain chemistry, hormone levels) 2) behavioral: either a
115	conscious or unconscious action or inaction in response to internal or external stimuli (e.g., dietary
116	intake, smoking, physical activity) 3) environmental: physical surroundings or conditions a person lives
117	or functions within (e.g., access to resources, air pollution, poor water quality, crime) 4) social: one's
118	experiences with relationships or interactions with others (e.g., racism/discrimination, intimate partner
119	violence, social support) [28, 29]

Articles were excluded if they were non-peer-reviewed publications, review/meta-analyses, and commentaries. Further, articles were excluded if outcomes were not specific to pregnant/postpartum individuals (i.e., partner, support persons, infant), determinants investigated were not related to depression or depression symptoms (e.g., post-traumatic stress disorder), and the outcome or evaluation of depression or depression symptoms were specific to a discrete facet of the perinatal period with implied potential for psychological consequences (i.e., abortion, fetal/infant loss, surrogacy, adoption).

126 Article selection and quality appraisal

After all articles were compiled and duplicates were removed, six authors (KDL, MLW, KAL,
SG, TCN, OFR) independently screened the titles and abstracts to determine which articles met
inclusion criteria. All articles were then subsequently cross-checked by the primary author to make a
final determination on inclusion. Of the articles that remained after the title and abstract screening, five
authors (KDL, MLW, SG, TCN, OFR) independently completed a full-text review. Any concerns

related to inclusion during any of the screening processes were resolved by discussion among theprimary author and the respective co-author.

134	Quality appraisal screening was independently conducted by two authors (KDL, TCN) to
135	ascertain any methodological or risk of bias concerns. Since quality appraisal assessments can be
136	subjective in nature, we selected two commonly used quality appraisal tools (i.e., Critical Appraisal
137	Skills Programme [CASP] and AXIS), respective to study design, to guide and standardize the process
138	[30, 31]. The studies were then categorized as having a low, moderate, high, or unclear risk of bias per
139	three types of bias (i.e., selection bias, recall bias, measurement bias). The types of bias and levels of
140	risk are defined in <b>Table 1</b> .

141 Table 1. Definitions of types of bias and level of risk

Term	Definition
Selection bias	any non-random error in methodological decisions that influence how a study sample is acquired.
Recall bias	occurs when the data collected from the participant may not be an accurate representation of the event or information being investigated given the lapse in time from when the event occurred to when the participant is being asked to recount information about the event.
Measurement bias	any non-random error in how an outcome is measured or evaluated.
Low risk of bias	sufficient information about the methods of investigation is provided, and there are minimal concerns related to risk of bias that could compromise the validity of the findings.
Moderate risk of bias	a majority of information about the methods of investigation are provided and/or a few concerns related to risk of bias were noted that could potentially influence the validity of the findings.
High risk of bias	a significant amount of essential information about the methods of investigation are not provided and/or a considerable number of concerns related to risk of bias were noted that likely compromise the validity of the findings.
Unclear risk of bias	too few methodological details were reported by the investigators to allow for a genuine determination of the level of risk of bias.

142

# 143 **Data extraction and synthesis**

The following data were extracted from the included articles: country, purpose or aims, study design, recruitment and sampling method, perinatal period investigated, number of time points, sample description, what determinants were investigated, methods for measuring determinants and depression, method of analysis, and findings related to the relationship among determinants and depression or depression symptoms. Once data extraction was complete, the data were organized by descending date respective to the time-period investigated (i.e., pregnancy, postpartum, perinatal) and then synthesized.

# **Results and discussion**

151 The PRISMA flow diagram provides an overview of the search results **Fig 1**. Twenty-six articles

remained for full-text review and quality appraisal screening. One article was excluded [32] during

153 quality appraisal screening due to methodological concerns making the total articles included 25 [33–

154 57]. An overview of included articles with statistical values of significant findings per perinatal period

155 can be found in **Tables 2-4**.

156

#### Fig 1. PRISMA flow chart diagram.

157	Table 2. Summary of included articles (pregnancy).
-----	--

PREGNANCY							
First Author	Purpose/Aims	Design <sup>#</sup>	Factor Domain	Summary of significant findings (values)			
Miyake <sup>2</sup> (2022) (N = 1744) <i>Japan</i>	Examine the association between tryptophan intake and depressive symptoms during pregnancy.	Cross- sectional <sup>1</sup>	Bh	<b>Tryptophan intake</b> was <i>positively associated</i> with being <b>unemployed</b> ( $p = 0.0001$ ), <b>household income</b> ( $p = 0.002$ ), <b>education</b> ( $p = 0.01$ ), and intake levels of <b>saturated fatty acids</b> ( $p \le 0.0001$ ), <b>eicosapentaenoic</b> <b>acid plus docosahexaenoic acid</b> ( $p \le 0.0001$ ), <b>calcium</b> ( $p \le 0.0001$ ), <b>vitamin D</b> ( $p \le 0.0001$ ), <b>isoflavones</b> ( $p \le 0.0001$ ), <b>fish</b> ( $p \le 0.0001$ ) and <i>negatively associated</i> with having ever <b>smoked</b> ( $p = 0.0006$ ) and <b>cereal intake</b> ( $p \le 0.0001$ ). <b>Age</b> was <i>negatively associated</i> to the prevalence of depressive symptoms during <u>pregnancy</u> in a crude analysis ( $p = 0.02$ ). Compared with <b>tryptophan intake</b> in the <u>lowest quartile</u> , <b>tryptophan intake</b> in the <u>highest quartile</u> was related to a $\downarrow$ prevalence of depressive symptoms during <u>pregnancy</u> . The <i>inverse exposure – response</i> relationship was also significant in the <i>crude analysis</i> .			

				<b>↑</b> tryptophan intake was independently <u>negatively</u> <u>associated</u> with the prevalence of depressive symptoms during <u>pregnancy</u> : the <i>adjusted PRs</i> (95% CIs) for depressive symptoms during <u>pregnancy</u> in all <u>four</u> <u>quartiles</u> of tryptophan intake ( <i>Crude PR (95% CI)</i> , 1.00; 0.95 (0.74–1.22); 0.87 (0.67–1.12); 0.57 (0.42–0.76), $p=0.0001$ )); ( <i>Adjusted PR (95% CI)</i> , 1.00; 0.99 (0.76–1.28); 0.94 (0.71–1.25); 0.64 (0.44–0.93), p=0.04)). These results were not changed when controlling for dietary factors.
				<b>Spontaneous preterm birth (SPTB)</b> was 2 times more <i>frequent</i> among those with depression compared to those without (12.4 vs. 6.3%, OR: 2.1 [95% CI: 1.10-4.04], $p = 0.02$ )
	1) Determine whether antenatal depression	Prospective <sup>2</sup>		Those with depression had $\uparrow$ levels of specific gravity corrected <b>8-isoprostane</b> compared to those without depression (geometric mean: 299.96 pg/mL vs. 237.01 pg/mL, $p = 0.001$ ).
®Venkatesh <sup>2</sup> (2019) (N = 462)	antenatal depression was associated with two biomarkers of oxidative stress, 8- OHdG and 8- Isoprostane, and five biomarkers of inflammation. 2) assess whether the association between antenatal depression and SPTB was mediated by those biomarkers found to be significant in the primary aim.		В	Those with depression who had <u>prenatal antidepressant</u> exposure had $\downarrow$ levels of 8-isoprostane compared to those who had depression <u>without antidepressant exposure</u> (geometric mean: 362.40 pg/mL, $p = 0.03$ ); however, both groups (antidepressant exposure vs. not) had $\uparrow$ 8- isoprostane levels compared to those without <u>prenatal</u> depression (237.01 pg/mL, ANOVA $p = 0.02$ ).
US				Prenatal depression was associated with <b>SPTB</b> (AOR: 2.09, 95% CI: 1.09-4.03, $p = 0.02$ ). The association between <b>8-isoprostane</b> and <u>prenatal</u> depression with <b>STPB</b> were $\downarrow$ when analyzed in the same regression model, which is suggested by the authors to indicate partial mediation of <b>8-isoprostane</b> on the relationship between <u>prenatal</u> depression and <b>SPTB</b> (AOR for <b>8-</b> <b>isoprostane</b> : 3.72, 95% CI: 2.14-6.46, $p < 0.001$ ; AOR prenatal depression: 1.68, 95% CI: 0.85-3.34, $p = 0.13$ ). After bootstrapping over 1,000 iterations, it was found that 27% of the effect of <u>prenatal</u> depression on <b>SPTB</b> was explained by <b>8-isoprostane</b> .
				No significant findings were noted for <b>8-OHdG</b> or inflammatory markers.
	Investigate if subjects with depression in	ith depression in regnancy had higher vels of pro – Case flammatory markers control <sup>1</sup> nd lower levels of nti-inflammatory		Compared to controls, those with <u>prenatal</u> depression had $\downarrow$ levels of <b>omega-3 polyunsaturated fatty acid (3-</b> <b>PUFAs)</b> ( $p = 0.026$ ), <b>EPA</b> ( $p = 0.019$ ), and <b>DHA</b> ( $p = 0.02$ ). They also had <b>î n-6/n-3 ratios</b> . <b>TNE</b> a way the only inflammation marker found to be
$\begin{array}{c} \text{Chang} \\ (2018) \\ (N = 33) \end{array}$	with depression in pregnancy had higher levels of pro – inflammatory markers and lower levels of anti-inflammatory markers.		В	<b>TNF-</b> $\alpha$ was the only <b>inflammatory marker</b> found to be significantly $\uparrow$ for those with <u>prenatal</u> depression versus those without ( $p = 0.016$ ).
(N = 33) Taiwan				No <i>correlation</i> between depression severity <b>PUFAs</b> and <b>inflammatory markers</b> were found. Depression duration was <i>negatively correlated</i> with <b>total n-3 PUFAs</b> , <b>EPA</b> and <b>DHA</b> ( $r = -0.415, -0.395, -0.392, p = < 0.05$ ). Current depression was <i>positively correlated</i> with <b>n-6/n-3</b> ratio and <b>TNF-a</b> ( $r = 0.458, 0.443, p < 0.01$ ).

®Finy <sup>2</sup> (2018) (N = 214) US	Examine the association between childhood abuse, low socioeconomic status (SES) and inflammatory markers during pregnancy	Cross- sectional <sup>1</sup>	B, S	Childhood abuse history was positively associated with CRP and IL-6. Current SES and CRP and IL-6 were negatively associated (p's < 0.01).
®Miller <sup>2</sup> (2018) (N =170) <i>US</i>	To evaluate the association between psychotropic medication and maternal serum inflammatory biomarkers in women with antenatal depressive symptoms (ADS) in the mid- trimester.	Cross- sectional <sup>1</sup>	В	Those with <u>untreated depression</u> were more likely to be from a <b>racial/ethnic minority</b> group, to have a $\downarrow$ <b>household income</b> , to be <b>publicly insured</b> , have a $\downarrow$ <b>educational level</b> , and $\downarrow$ likely to be <b>married</b> . Further, they were $\uparrow$ likely to be <b>employed</b> than those with depression <u>non-responsive to treatment</u> but were $\downarrow$ likely to be <b>employed</b> than those with depression <u>responsive to</u> <u>treatment</u> . There were no differences noted in serum levels of <b>IFNy</b> , <b>IL13, IL6, IL8,</b> or <b>CRP</b> , but <b>TNF-</b> <i>a</i> differed across the groups. <i>Post-hoc</i> analyses indicated those <u>non-responsive</u> to treatment ( $p = 0.02$ ) and <u>untreated depression</u> ( $p =$
				0.01) had $\checkmark$ <b>TNF-</b> $\alpha$ compared to those <u>responsive to</u> <u>treatment</u> . No differences noted between <u>untreated</u> <u>depression</u> and those <u>non-responsive to treatment</u> ( $p = 0.76$ ). When controlling for <b>race/ethnicity, income</b> , and <b>marital</b> <b>status</b> , a <i>linear regression</i> demonstrated both those with
				depression who were <u>non-responsive</u> to treatment and those who had <u>untreated</u> depression had $\uparrow$ <b>TNF-</b> <i>a</i> compared to those <u>responsive</u> to treatment ( $\beta = 0.27, 95\%$ <i>CI:</i> 0.02-0.52 and $\beta = 0.23, 95\%$ <i>CI</i> 0.02-0.44).
	<ul><li>7) pregnant women's</li><li>90) close relationships and</li></ul>	Prospective <sup>2</sup>	B, S	<i>Correlations</i> between <b>cytokines</b> varied within <u>each</u> <u>trimester</u> and ranged from $r = 0.660 - r = -0.469$ with a <i>mean</i> $r = 0.322$ indicating a good proportion of variance in each <b>cytokine</b> is unique.
				Romantic partner (RP) relationships with positive features (i.e., support/closeness) were associated with ↓ levels of inflammatory cytokines; RP relationships low in both positive and negative features (indifferent) were associated with cytokine profiles indicating ↑ inflammation.
®Ross (2017) (N = 90) <i>US</i>				Positive RP relationship was negatively associated with IL6:IL10 ratio. Further, when positive RP features were ↑ and there were ↓ RP negative features, the estimated IL6:IL10 ratios were lowest indicating a potential buffering or protective effect of positive RP relationships.
				<b>Positive</b> and <b>negative RP relationships</b> were <i>associated</i> with <b>IL10</b> levels ( $b(SE) = 0.031$ ( $0.009$ ), $p = 0.001$ ; $b(SE) = 0.017$ ( $0.007$ ), $p = 0.017$ ).
				<b>Positive</b> and <b>negative RP relationships</b> were associated with <b>IFNy</b> levels ( $b(SE) = 0.131$ (0.041), $p = 0.002$ ; b(SE) = 0.095 (0.032), $p = 0.004$ )
				Neither <b>positive</b> and <b>negative RP relationships</b> were <i>associated</i> with <b>IL13, IL8, IL6,</b> and <b>TNF-</b> <i>α</i> levels.

				↑ positive RP relationship was associated with ↓ depressed mood ( $r = -0.35$ , $p = 0.001$ ) and perceived stress ( $r = -0.41$ , $p < 0.001$ ) whereas ↑ negative RP relationship was associated with ↑ depressed mood ( $r = 0.51$ , $p < 0.001$ ), perceived stress ( $r = 0.53$ , $p < 0.001$ ), and pregnancy distress ( $r = 0.29$ , $= 0.005$ ).
				When controlling for <b>pre-pregnancy BMI</b> , $\uparrow$ depression scores were <i>associated</i> with $\uparrow$ levels of <b>IL-6</b> ( $\beta = .23$ , $t(2, 55) = 1.98$ , $p = 0.05$ ).
				↑ depression scores were marginally <i>associated</i> with ↑ <b>TNF-α</b> levels ( $β = 0.24$ , t(2, 58), $p = 0.06$ ).
	Examine associations among perceived stress, current			Depressive symptoms were <i>positively correlated</i> with <b>perceived stress</b> ( $r = 0.050$ , $p < 0.01$ ).
©Christian (2009) (N = 60) US	depressive symptoms, and serum inflammatory markers among pregnant	Cross- sectional <sup>1</sup>	B, Bh	Those classified as <b>unhappy about their pregnancies</b> had $\uparrow$ depressive symptoms compared to those who were happy about their pregnancy <i>(mean CES-D = 22, SD = 10; mean CES-D = 16, SD = 10, p = 0.04).</i>
	women from primarily lower socioeconomic backgrounds.			Those reporting $\downarrow$ social support had $\uparrow$ depressive symptoms ( $p < 0.05$ ), and those with $\uparrow$ frequent hostile and insensitive social interactions also had $\uparrow$ depressive symptoms ( $p < 0.01$ ).
				After <i>controlling</i> for <b>social support</b> , <b>hostile and</b> <b>insensitive social interactions</b> remained <i>associated</i> with depressive symptoms ( $\beta = 0.17$ , $r(1, 59) = 1.25$ , $p = 0.21$ ).

Author<sup>2</sup> = secondary analysis; Design<sup>#</sup> = Design + Number of timepoints investigated; Domain of factors investigated in relation to depression: B = Biological, Bh = Behavioral, E = Environmental, S = Social; *Values (when provided)* = statistical values respective to analysis; Factors investigated in relation to depression **bold;** Timeframe and/or groups investigated <u>underlined.</u> (\*\*\*)

#### Table 3. Summary of included articles (postpartum).

POSTPARTUM							
First Author	Purpose/Aims	Design <sup>#</sup>	Factor Domain	Summary of significant findings (values)			
Achytes (2022) (N = 130) US	Investigate whether a pro-inflammatory status in plasma, together with changes in the kynurenine pathway activity, is associated with the development of severe depression and suicidal behavior in the post-partum.	Case- control <sup>1</sup>	B, Bh	↑ IL-6, IL-8 ↑ PPD (OR IL-6 = 3.0, 95% CI = 1.37 – 6.6; OR IL-8 = 3.32, 95% CI = 1.32 – 8.34, per pg/ml increase) ↓ IL-2 ↑ PPD (OR = 2.34, 95%CI = 1.35–4.05, p = 0.002, per pg/ml decrease) ↓ serotonin ↑ odds of PPD (OR = 1.43 per nM decrease in serotonin, 95% CI: 1.07 – 1.92, p = 0.016) ↑ Kynurenine/serotonin ratio ↑ PPD (OR = 1.35 per unit increase, 95% CI: 1.03 – 1.79, p = 0.038) Sensitivity analysis using depression scores: models for IL-8, IL2, serotonin, serotonin/kynurenine, and quinolinic acid were significant; (linear regression, Beta 3.9, Standardized Beta 0.22, p = 0.006), (linear regression, Beta –2.3, Standardized Beta –0.23, p = 0.005), (linear regression, Beta –1.3, Standardized Beta -0.24, p = 0.003), linear regression, Beta –1.1, Standardized Beta 0.22, p = 0.009), linear regression, Beta –4.3, Standardized Beta –0.18, p = 0.022)			

Dhiman <sup>2</sup> (2021) (N = 660) <i>India</i>	Explore the association between vitamin B12 and probable PPD in South Indian population.	Cross- sectional <sup>1</sup>	В	↓ serotonin was <i>associated</i> with current and history of suicidal behavior and ↑ <i>odds</i> of completed suicide attempt during pregnancy. ( <i>OR</i> : 0.51[0.32, 0.8]1, <i>p</i> = 0.005), ( <i>OR</i> : 0.50 [0.29, 0.87], <i>p</i> = 0.013), ( <i>OR</i> : 0.51, [0.31, 0.84], <i>p</i> = 0.007) Those with probable depression were ↑ likely to belong to the middle SES group ( <i>p</i> = 0.002), had more than one child ( <i>p</i> = 0.002), be dissatisfied with their marriage ( <i>p</i> < 0.001), be dissatisfied with the gender of their child ( <i>p</i> < 0.001), and had ↑ rates of cesarean delivery ( <i>p</i> = 0.012), and egg ( <i>p</i> = 0.002) intake. Median total B12 levels and cB12 were ↓ in cases compared to <u>controls</u> ( <i>p</i> < 0.001). Methyl malonic acid (MMA) – marker of functional deficiency of vitamin B12 – was ↑ cases compared to controls ( <i>p</i> = 0.002). After <i>adjusting</i> for SES, martial dissatisfaction, unplanned pregnancy, and type of delivery, the <i>regression model</i> indicated the likelihood of postpartum depression to ↓ by 0.39 for ever unit ↑ in total vitamin B12 ( <i>OR</i> = 0.394; 95% <i>CI</i> : 0.189-0.822, <i>p</i> = 0.009) and by a factor of 0.29 ( <i>OR</i> = 0.293; 95% <i>CI</i> : 0.182-0.470, <i>p</i> < 0.001) for cB12. MMA ( <i>OR</i> = 2.04; 95% <i>CI</i> : 1.53-2.11, <i>p</i> < 0.001) and 5-methyl tetrahydrofolate (THF) ( <i>OR</i> = 3.18; 95% <i>CI</i> : 1.42-6.08, <i>p</i> = 0.001) were found to be predictors of PPD. After <i>adjusting</i> for SES, martial dissatisfaction, unplanned pregnancy, and type of delivery, a significant <i>negative</i> association among serotonin and depression remained ( <i>β</i> = -0.16, <i>p</i> = 0.005), as did a <i>positive association</i> among MMA ( <i>β</i> = 0.161, <i>p</i> = 0.001), homocysteine (hcy) ( <i>β</i> = 0.155, <i>p</i> = 0.005), and THF ( <i>β</i> = 0.118, <i>p</i> = 0.010) and depression.
Rihua <sup>2</sup> (2018) (N = 84) <i>China</i>	To determine associations between PPD and plasma neurotransmitters.	Case control <sup>1</sup>	В	There were significant differences in <b>education</b> and <b>mode</b> of <b>delivery</b> among those with <u>PPD</u> and those <u>without</u> . Plasma levels of <b>serotonin</b> ( <b>5-hydroxytryptamine or 5-</b> <b>HT</b> ) and <b>neuropeptide Y</b> ( <b>NPY</b> ) were $\downarrow$ in those with <u>PPD</u> compared to <u>controls</u> ( $p < 0.05$ or $p < 0.01$ ) whereas <b>norepinephrine</b> ( <b>NE</b> ) and <b>substance P</b> ( <b>SP</b> ) were $\uparrow$ in <u>PPD</u> cases versus <u>controls</u> ( $p < 0.05$ ). No differences were found for <b>dopamine</b> ( <b>DA</b> ). A <i>negative correlation</i> among depression scores and <b>serotonin</b> and <b>NPY</b> ( $p < 0.05$ or $p < 0.01$ ) were present as well as a <i>positive correlation</i> among depression scores with <b>NE</b> and <b>SP</b> ( $p < 0.01$ or $p < 0.01$ ).
Veen (2016) (N = 42) Netherlands	To investigate if alterations in tryptophan degradation in the postpartum period are	Case control <sup>1</sup>	В	Those considered to be <u>"healthy" postpartum</u> participants were $\uparrow$ likely to be <b>breastfeeding</b> at the time of blood collection ( $p < 0.001$ ).

			. <u> </u>	
	associated with the occurrence of postpartum depression and postpartum psychosis.			Physiological postpartum period:Healthy postpartum (PP) participants had $\checkmark$ serum levelsof kynurenic acid (KA) compared to healthy non-PPcontrols ( $p < 0.001$ ).All PP participants had $\uparrow$ levels of 3-OH-kynurenine
				<b>(3HK)</b> ( $p = 0.011$ ); the <b>KA/kynurenine (KYN) ratio</b> was $\downarrow$ in <u>healthy PP participants</u> ( $p < 0.001$ ) suggesting a strong inhibition of the <b>kynurenine aminotransferases</b> <b>(KAT) enzymes</b> during the first <u>2 months PP</u> .
				The <b>3HK/KYN ratio</b> was $\uparrow$ in <u>healthy PP</u> participants with a median time of <u>22 days PP</u> ( $p = 0.021$ ), but not in <u>healthy PP</u> participants with a median time of blood collection <u>40 days PP</u> . The authors suggest this indicates $\uparrow$ activity of the <b>kynurenine-3-monooxygenase</b> ( <b>KMO</b> ) <b>enzymes</b> in the <u>first month</u> of the physiological <u>PP period</u> and then the gradual returning to "normal" levels.
				The serotonergic pathway (5HIAA)/KYN ratio was $\downarrow$ in <u>healthy PP</u> participants suggesting that the breakdown of <b>tryptophan (TRP)</b> is <i>biased towards</i> the <b>KYN</b> pathway and <i>away from the</i> <b>serotonergic</b> pathway in the physiological <u>PP period</u> ( $p = 0.009$ ).
				<u>"Healthy" PP participants</u> had $\downarrow$ serum levels of <b>TRP</b> ( $p < 0.001$ ), and $\uparrow$ levels of <b>KYN</b> ( $p = 0.002$ ) compared to <u>healthy non-PP</u> participants, and consequently the <b>TRP breakdown index</b> was also $\uparrow$ ( $p < 0.001$ ).
				<b>KYN</b> was $\downarrow$ in <u>cases</u> compared to <u>controls</u> $(p = 0.001)$ , and accordingly <u>cases</u> had a $\downarrow$ <b>tryptophan breakdown</b> <b>index</b> compared to <u>controls</u> $(p = 0.035)$ .
				<i>Associations</i> between <b>genetic polymorphisms</b> and PPD symptoms were significant only at the <u>6-week time point</u> , not at <u>6 months</u> (data not shown).
				<b>COMT-Val<sup>158</sup>Met</b> with <b>↑</b> risk for <b>Met carriers</b> was <i>associated</i> with <u>PPD</u> .
				Previous <b>psychiatric contact</b> , <b>significant life events</b> , and <b>maternity stressors</b> were <i>associated</i> with <u>PPD</u> symptoms.
Comasco (2011) (N = 272) Sweden	Examine whether genetic variations in the monoaminergic neurotransmitter system, together with environmental stressors, contribute to the development of PPD symptoms	Case control <sup>2</sup>	B, S	Gene-by-gene interactions were present for COMT- MAOA in relation to PPD symptoms. Low MAOA activity carriers with the Met variant of COMT was related to PPD symptoms; high MAOA activity variant was associated with PPD symptoms only when <u>combined</u> with the Met allele of COMT; short 5HTT allele was associated with PPD symptoms only when <u>combined</u> with the Met allele of COMT.
	TTD Symptoms			<b>COMTVal</b> <sup>158</sup> Met was associated with PPD symptoms in the presence of <b>previous psychiatric contact</b> and <b>maternity stressors</b> , while <b>MAOA-uVNTR</b> was associated with PPD symptoms only in the presence of maternity stressors.
				The <i>logistic regression analysis</i> demonstrated an <i>association</i> among PPD symptoms and <i>COMT</i> Val <sup>158</sup> Met, <b>previous psychiatric contact</b> , and <b>maternity stressors</b> . The <i>model explained 30% variance</i> . After stratifying for previous psychiatric contact, the gene-environment

				interaction model indicated those with <b>previous</b> <b>psychiatric contact</b> had a <i>main effect</i> of <b>COMT-</b> <b>Val<sup>158</sup>Met</b> and <b>5HTT-LPR</b> with an <i>explained variance of</i> 40%.
Bailara (2006) (N =50) <i>France</i>	Assess the correlation of intensity of baby blues, with the intensity of metabolic changes and brain tryptophan availability	Cross- sectional <sup>1</sup>	В	Total plasma <b>TRP</b> exhibited a <i>mild</i> (+19%) <b>↑</b> . An abrupt <b>↑</b> in <b>competitor amino acid</b> concentrations (+77% <b>isoleucine</b> , +55% <b>leucine</b> , +52% <b>tyrosine</b> ) led to a $\downarrow$ in <b>brain tryptophan availability (BTAI)</b> . The <b>BTAI</b> $\downarrow$ between the <u>prenatal</u> and <u>postpartum</u> period (-15%, $p < 0.01$ ) and was <i>associated</i> with PP blues symptoms. The change in <b>BTAI</b> was <i>negatively correlated</i> with the intensity of postpartum blues ( $r = -0.283$ , $p < 0.05$ ).
Moses- Kolko <sup>2</sup> (2008)	To measure brain serotonin-1A (5HT1A) receptor binding potential (BP)	Cross-	В	There was an effect of <b>breastfeeding status</b> on <b>hypothalamic-pituitary-ovarian axis</b> hormone concentrations <b>estradiol</b> , <b>progesterone</b> , <b>LH</b> , <b>FSH</b> , and <b>prolactin</b> [Wilks' lambda = 0.2056; $F(5, 10) = 7.73$ , $p = 0.003$ ]. A post-hoc analysis showed <b>breastfeeding</b> was associated with $\downarrow$ <b>estradiol</b> [ $F(1, 14) = 8.31$ , $p = 0.01$ ], <b>progesterone</b> [ $F(1, 14) = 4.33$ , $p = 0.06$ ], and <b>FSH</b> <b>concentrations</b> [ $F(1, 14) = 5.18$ , $= 0.04$ ] and $\uparrow$ <b>prolactin</b> <b>concentrations</b> [ $F(1, 14) = 26.25$ , $p = 0.0002$ ]. Serotonin receptor ( <b>5HT1A</b> ) binding in the three <i>a prior</i> regions of interest ( <b>mesiotemporal cortex</b> , left lateral <b>orbitofrontal cortex</b> , and <b>subgenual anterior cingulate</b> <b>cortex</b> ) demonstrated a main effect of depression [ $F(3, 12) = 13.67$ , Wilks' lambda = 0.23, $p = 0.0004$ ].
(N =16) US	in healthy and depressed postpartum women.	sectional <sup>1</sup>		Post hoc analysis detected significant depression effects on $\downarrow$ in the <b>mesiotemporal cortex</b> [21.6% mean decrease; F(1, 140 = 22.5, p = 0.0003], <b>subgenual</b> <b>cingulate cortex</b> [27.65 mean decrease; F(1, 14) = 23.4, p = 0.0002], and <b>left lateral orbitofrontal cortex</b> [17.9% mean decrease; F(1, 14) = 7.13, p = 0.018] regions. There were also associations with reductions in the secondary ROI [F(5, 10) = 3.24, Wilks' lambda = 0.38, p = 0.054], and the most significant $\downarrow$ were in the <b>right</b> <b>lateral orbitofrontal cortex</b> [23.4% mean decrease; F(1, 14) = 8.72, p = 0.011] and <b>pregenual anterior cingulate</b> <b>cortex</b> [23.4% mean decrease; F(1,14) = 17.2, p = 0.001].

165 166 167

Author<sup>2</sup> = secondary analysis; Design<sup>#</sup> = Design + Number of timepoints investigated; Domain of factors investigated in relation to depression: B = Biological, Bh = Behavioral, E = Environmental, S = Social ; Values (when provided) = statistical values respective to analysis; Factors investigated in relation to depression **bold**; Timeframe and/or groups investigated <u>underlined</u>. 168 ®Study reported race/ethnicity

169 170

#### Table 4. Summary of included articles (perinatal).

PERINATAL					
First Author	Purpose/Aims	Design#	Factor Domain	Summary of significant findings (values)	
®Sha (2022) (N =114) US	To determine whether cytokines and kynurenine metabolites can	Prospective <sup>4</sup>	В	<b>↑ IL-1β</b> , <b>IL-6</b> , and <b>QUIN</b> were <i>associated</i> with <b>↑</b> depression severity and/or <b>↑</b> <i>odds</i> of having depression (Percent change in OR(CI): 32.3% (7.0, 63.6), 58.4% (22.1, 111.7), 91.6% (15.0, 232.0)	

	predict the development of depression in pregnancy.			<b>IL-6</b> performed best in <i>predicting</i> depressive symptoms; however, <b>KYN</b> , <b>QUIN</b> , <b>KYN/TRP ratio</b> ( <b>rKT</b> ) also produced good predictions ( $AUC = 0.79$ and $0.8$ by <i>Bayesian ordinal and logistic regression, respectively;</i> ROC AUC > 0.7). Precision recall analyses confirmed predictive value of model. The <i>leave-one-out cross validation</i> method indicated the predictability of the model would be optimal from <u>mid- to</u> <u>late pregnancy</u> ( $2^{nd}$ to $3^{rd}$ trimester). The <b>full model</b> nominally outperformed <b>individual markers</b> for <i>predicting</i> risk of significant depressive symptoms. <i>Ordinal</i> and <i>logistic regression</i> full models had <i>ROC</i> AUC = 0.83, <i>PR</i> $AUC = 0.41$ .
®Kimmel (2022) (N = 30) <i>US</i>	Analyze trajectories of serotonin and tryptophan-related metabolites, bile acid metabolites, and microbial composition related to psychiatric history and current symptoms across the perinatal period.	Pilot <sup>3</sup>	В	Fiber consumption was slightly $\downarrow$ in <u>cases</u> compared to <u>controls</u> (determined too small a sample to calculate p-values). Mean serotonin level $\uparrow$ from pregnancy to postpartum ( $p = 0.0002$ for $3^{rd}$ trimester (V2) to 5-10 weeks postpartum (V3); $p = 0.002$ for $1^{st}$ or $2^{rd}$ trimester (V1) to V3). NEOP level trajectories followed a different pattern than serotonin by $\uparrow$ from <u>V1 to V2</u> ( $p < 0.0001$ ) and the $\downarrow$ postpartum ( $p = 0.005$ ). Mean KYN $\uparrow$ from <u>V1 to V2</u> ( $p = 0.003$ ) and $\uparrow$ again from <u>V2 to V3</u> ( $p = 0.004$ ). The KYN/TRP ratio was $\uparrow$ at <u>V2 and V3</u> compared to <u>V1</u> ( $p < 0.0001$ ; $p < 0.0001$ ). KA was $\uparrow$ at <u>V3</u> compared to <u>V1</u> ( $p < 0.0001$ ; $p < 0.0001$ . KA was $\uparrow$ at <u>V3</u> compared to both <u>V2</u> ( $p = 0.003$ ) and <u>V1</u> ( $p = 0.0004$ ). <b>Primary bile acids:</b> Chenodexycholic acid (CDCA) $\uparrow$ from V2 to V3 ( $p < 0.0001$ ) with an overall $\uparrow$ from earlier <u>V1</u> to V3 ( $p = 0.0003$ ); Glycochenodeoxycholic acid (GCDCA) $\uparrow$ from <u>V2 to V3</u> ( $p < 0.0001$ ). Taurochenodeoxyccholia teid (GCA) $\uparrow$ from <u>V1 to V2</u> ( $p = 0.003$ ) and $\uparrow$ from <u>V1 to V3</u> ( $p = 0.001$ ). Glycocholic acid (GCA) $\uparrow$ from <u>V1 to V2</u> ( $p = 0.003$ ); Taurochenodeoxyccholic acid (GCA) $\uparrow$ from <u>V1 to V2</u> ( $p = 0.0001$ ). and $\downarrow$ from <u>V2 to V3</u> ( $p < 0.0001$ ). and $\downarrow$ from <u>V2 to V3</u> ( $p < 0.0001$ ). <b>Secondary bile acids:</b> Glycoursodeoxcholic acid (GUDCA) $\downarrow$ from <u>V2 to V3</u> ( $p < 0.0001$ ); divecholic acid (GUCA) $\downarrow$ from <u>V2 to V3</u> ( $p < 0.0001$ ); and Levels of Glychoycholic acid (GHCA) and GLCA remained $\uparrow$ from <u>V1 to V3</u> ( $p < 0.0001$ ); Glycolithocholic acid (TLCA), and tarodeoxycholate hydrate (TDCA) $\downarrow$ from <u>V2 to V3</u> ( $p < 0.0001$ ; $p = 0.0003$ ; $p = 0.0003$ ; $p < 0.0001$ ; $p = 0.0003$ ; $p = 0.0001$ ; $p = 0.0003$ ; $p < 0.0001$ ; $p = 0.000$

				Metabolites and microbiome:         Alpha diversity did not significantly change across the perinatal period. ↑ bile acid GUDCA and UDCA levels were associated with ↓ alpha-diversity across all 4 indices (evenness, Faith's phylogenetic diversity, count of observed OTUs, Shannon entropy).         ↑ CDCA was associated with ↓ alpha diversity for the evenness index and Shannon index only, and also only when first trimester participants were included.         Certain bacterial genera were associated with UDCA
				and <b>TUDCA</b> , primarily in the order <b>Clostridiales</b> and family <b>Cachnospiraceae</b> . <b>THcA</b> was also <i>associated</i> with <b>Riseburia</b> .
®Tebeka <sup>2</sup> (2021) (N = 3,252) <i>France</i>	Assess the relationship between childhood trauma (CT) and perinatal depression, considering types of CT	Case control <sup>3</sup>	S	UDCA was the only metabolite associated with psychiatric history ( $q = 0.033$ ). Those reporting childhood trauma (CT) were ↑ likely to be < 26 years old (8.1% vs. 4.5%; $OR = 1.8$ ; 95% CI: 1.2-2.6) > 39 years old (11% vs. 7%; $OR = 1.9$ ; 95% CI: 1.2-2.9), single (6.7% vs. 2.7%; $OR = 2.6$ ; 95% CI: 1.5- 4.2), have a lower level of education (18.1% vs. 6.8%; OR = 3.0; 95% CI: 1.8-3.6), and ↑ likely to have been unemployed (14.1% vs. 6.1%; $OR = 2.5$ ; 95% CI: 1.8- 3.6). Those with CT had a ↑ risk of either depression, anxiety, or suicide attempts compared those without (61.6% vs. 40.8%; $OR = 2.3$ ; 95% CI: 1.8-2.9), and a personal history of depression, anxiety, or suicide attempts were ↑ frequent in those with CT (depression: $OR = 2.2$ ; 95% CI: 1.7-2.7; anxiety: $OR$ = 2.3; 95% CI: 1.7-3.0; suicide attempt: $OR = 5.4$ ; 95% CI: 3.5-8.4) Depression was ↑ common in those with a CT regardless of type of CT, and the difference was significant for emotional, physical, and sexual abuse as well as emotional neglect ( $p < 0.05$ for each). The types of CT demonstrated specific associations with different timing of depression onset. Emotional neglect was associated with depression during pregnancy ( $aOR = 2.1$ ; 95% CI: 1.2-3.8, $p = 0.012$ ); sexual abuse with both <u>early and late</u> onset PPD ( $aOR = 2.3$ ; 95% CI: 1.2-4.6; $aOR = 2.4$ ; 95% CI: 1.2-4.9, respectively); emotional abuse was associated only with late PPD ( $aOR = 2.7$ ; 95% CI: 1.4- 5.1). A dose effect was present between CT types and risk of depression. When 1 type of CT was present there was a ↑ risk of depression ( $aOR = 1.6$ ; 95% CI: 1.1-2.3, $p =$ 0.015), whereas, when 2+ types of CT were present the risk further ↑ ( $aOR = 2.1$ ; 95% CI: 1.3-3.3) even after adjusting for history of depression and sociodemographic covariates.
Nazzari (2020) (N = 97) <i>Italy</i>	1) Describe the cross- sectional and longitudinal association between	Prospective <sup>4</sup>	В	↑ prenatal <b>Kyn</b> levels were <i>associated</i> with ↓ depressive symptoms in <u>late pregnancy</u> ( <i>estimate</i> = - 0.002, SE = 0.001, $p = 0.03$ ) after adjusting for maternal age.

	tryptophan, kynurenine, and kynurenine/tryptophan ratio and depression symptoms in late pregnancy through the first year postpartum 2) examine the role of inflammatory (IL-6) and stress (cortisol) markers in moderating any associations 3) determine if specific to depressive symptoms or can be replicated with anxiety given high concurrence of these disorders			<b>Pre-pregnancy BMI</b> was mildly <i>associated</i> with <b>IL-6</b> levels ( $r = 0.23$ , $p = 0.03$ ) in preliminary analysis but adjusting models for <b>BMI</b> did not alter the direction or significance of findings. <b>Model 2:</b> There was a <i>three-way interaction</i> among <u>prenatal</u> <b>Trp</b> <b>levels</b> , <b>IL-6</b> , and slopes of <b>time</b> on depression scores ( $ps < 0.05$ ). $\downarrow$ levels of <u>prenatal</u> <b>Trp</b> and $\uparrow$ <b>IL-6</b> were <i>associated</i> with $\uparrow$ depressive symptoms in <u>late pregnancy</u> ( $p = 0.04$ ) and with the change in depressive symptoms from <u>pregnancy</u> to three postpartum time points ( $ps = 0.04$ ). <b>Model 3:</b> A <i>three-way interaction</i> among the <b>KYN/TRP ratio</b> , <b>IL-6</b> , and the depression scores trajectory from <u>pregnancy to 12 months postpartum</u> . $\downarrow$ levels of <u>prenatal</u> <b>KYN/TRP</b> <b>ratio</b> and $\uparrow$ levels of <b>IL-6</b> were <i>associated</i> with $\uparrow$ depressive scores at <u>delivery</u> ( $p = 0.05$ ) and <u>12 months</u> postpartum ( $p = 0.004$ ) and with a flatter <b>trajectory</b> of change in depressive symptoms from <u>pregnancy to 12</u> months postpartum ( $p = 0.048$ ). Conversely, at $\uparrow$ levels of <b>KYN/TRP ratio</b> and $\uparrow$ <b>IL-6</b> levels were <i>associated</i> with a $\downarrow$ in depressive scores from <u>pregnancy to 3</u> ( $p = 0.03$ ) and <u>12 months</u> ( $p = 0.014$ ) postpartum.
	Identify trajectories of perinatal depressive symptoms and their predictors among low- income South African women who were already at risk of depression during pregnancy.	Prospective <sup>4</sup>	Bh, S, E	<b>Food insecurity</b> predicted classification of either prenatal only depression or prenatal and postpartum depression. The odds of being classified in the prenatal and postpartum depression trajectory was 2.5 greater (95% CI: 1.21-5.15; $p = 0.013$ ) among participants who reported being severely food insecure. Overall levels of social support at baseline $\checkmark$ the odds of
Garman <sup>2</sup> (2019) (N = 384) South Africa				belonging to the prenatal and postpartum depression class (OR = 0.97, 95% CI: 0.95-0.99; p = 0.011). When looking at specific <b>types of support</b> , only a $\uparrow$ level of <b>family support</b> ( $OR = 0.91, 95\% CI: 0.86-0.96; p =$ $0.001$ ) or $\uparrow$ level of <b>support</b> from a <b>significant other</b> ( $OR$ $= 0.94, 95\% CI: 0.88-1.00; p = 0.046$ ) $\downarrow$ the odds of being classified into the prenatal and postpartum depression class.
				Those who reported <b>IPV</b> at baseline were 2.8 times $\uparrow$ likely (95% CI: 1.23-6.52; $p = 0.014$ ) to belong to the prenatal and postpartum depression class.
				Odds of belonging to the prenatal and postpartum depression class were $\uparrow$ among those who reported greater functional impairment ( $OR = 1.03$ , 95% CI: 1.02-1.06; $p = 0.002$ ), heavy drinking during pregnancy ( $OR = 2.12$ , 95% CI: $0.03-4.37$ ; $p = 0.042$ ), had current ( $OR = 2.77$ , 95% CI: $1-32-5.80$ ; $p = 0.007$ ) or lifetime diagnosis of depression ( $OR = 2.85$ , 95% CI: 1.38-5.87; $p = 0.004$ ), and high risk of suicide ( $OR =2.58$ , 95% CI: $1.19-5.61$ ; $p = 0.017$ ).
Teshigawara (2019) (N = 132) <i>Japan</i>	To determine whether cytokines and kynurenine metabolites can predict the development of	Prospective <sup>3</sup>	В	In the <u>non-depressed group</u> : <b>TRP</b> , <b>KYN</b> , <b>3HK</b> , and <b>KA</b> were $\uparrow$ <u>postpartum</u> compared to <u>pregnancy</u> (two-way repeated ANOVA, <b>Trp:</b> $F_{group}$ (3, 128) = 1.44, p = 0.234, $F_{period}$ (1, 128) = 64.3, p < 0.0001, $F_{group x period}$ (3, 128) = 0.376, p = 0.771; <b>Kyn:</b> $F_{group}$ (3, 128) = 0.927, p = 0.430, $F_{period}$ (1, 128) = 96.4, p < 0.01, $F_{group x period}$ (3, 128) = 6.09, p

			I	
	depression in pregnancy.			$< 0.01;$ <b>3HK</b> : $F_{group} (3, 128) = 0.0662, p = 0.978, F_{period} (1, 128) = 6.09, p < 0.05, F_{group x period} (3, 128) = 1.98, p = 0.120;KA: F_{group} (3, 128) = 1.52, p = 0.213, F_{period} (1, 128) = 2.11, p = 0.149, F_{group x period} (3, 128) = 5.32, p < 0.01).In the postpartum depressed group: KYN and KA were \uparrow during pregnancy, but 3HAA during the postpartum period was \downarrow than that of the non-depressed group. No differences were noted in TRP or its metabolites between the temporary gestational depressive group or the continuous depressive group and the non-depressive group.$
				The ratio of <b>KYN</b> in the <u>postpartum period</u> compared to that during <u>pregnancy</u> was significantly $\downarrow$ in the <u>postpartum depressive</u> group compared to the <u>non-</u> <u>depressive group</u> ( <i>one-way ANOVA</i> , $F(_{3, 128}) = 5.27$ , $p < 0.01$ ).
				In the postpartum depressive group <b>KYN/TRP</b> and <b>KA/KYN</b> ratio during pregnancy were $\uparrow$ than those in the non-depressive group. <b>KYN/TRP</b> during postpartum to that during pregnancy was significantly $\downarrow$ than the non-depressive group (one-way ANOVA, F (3, 128) = 4.54, p < 0.01).
				<b>KYN, KA, and KYN/TRP</b> , and <b>KA/KYN</b> ratio during <u>pregnancy</u> were $\uparrow$ and <b>3HAA</b> during <u>postpartum</u> was $\downarrow$ in the <u>postpartum</u> depressive group compared to <u>non-depressive group</u> .
				<b>KYN, KA,</b> and <b>KYN/TRP</b> during <u>pregnancy</u> was correlated with depression scores during the <u>postpartum</u> <u>period</u> ( <i>Pearson's correlation</i> : <b>KYN</b> : $r(_{77}) = 0.330$ , $p < 0.01$ , <b>KA</b> : $r(_{77}) = 0.278$ , $p < 0.05$ , <b>KYN/TRP</b> : $r(_{77}) = 0.229$ , $p < 0.05$ , <b>KA/KYN</b> : $r(_{77}) = 0.221$ , $p = 0.05$ ). There was a <i>negative relationship</i> between <b>3HAA</b> levels during <u>postpartum</u> period and depression scores ( <i>Pearson's</i> <i>correlation</i> : $r(_{77}) = -0.259$ , $p < 0.05$ ).
				The percentage of depressed participants was $\downarrow$ in the <b>intervention group</b> compared to the control group at week <u>38</u> (18.6% vs. 35.6%) ( $\chi^2 = 4.190$ ; $p = 0.041$ ) and at <u>6 weeks postpartum</u> (14.5% vs 29.8%) ( $\chi^2 = 3.985$ ; $p = 0.046$ ).
	Analyze trajectories of serotonin and			Significant differences were noted in the <i>multiple</i> imputation analysis at <u>38 weeks</u> (18.6% vs. 34.4%) ( $\chi^2 =$ 4.085; $p = 0.049$ ).
Vargas- Terrones (2017) (N = 124) Spain	tryptophan-related metabolites, bile acid metabolites, and microbial composition related to psychiatric history and current symptoms across the	Randomized control trial <sup>3</sup>	Bh	A <b>treatment effect</b> was found in the per-protocol ( $F_{2, 220}$ = 3.798; $p = 0.024$ ) and in the <i>simple imputation</i> ( $F_{2,244}$ = 3.351; $p = 0.037$ ) analyses. Differences were also found in the <i>group-time interaction</i> between gestational weeks 12-16 (baseline) and <u>6 weeks postpartum</u> ( $p = 0.014$ ) in the per-protocol analysis. Differences were found in the <b>group-time interaction</b>
	perinatal period.			between depression scores at <u>baseline</u> and <u>gestational</u> week 38 ( $p = 0.046$ ), and between <u>baseline</u> and <u>6 weeks</u> <u>postpartum</u> ( $p = 0.025$ ), with a $\downarrow$ depression score in the <u>intervention group</u> than in the <u>control group</u> . The participants considered to have <b>excessive gestational</b> weight gain, the <u>control group</u> had a $\uparrow$ percentage of depression at week 38 ( $\chi^2 = 9.489$ ; $p = 0.002$ ) and at <u>6</u>
				weeks postpartum ( $\chi^2 = 5.202; p = 0.023$ ).

				The percentage of depressed women was $\downarrow$ in the <b>intervention group</b> compared to the <u>control group at</u> week 38 for those with <b>pre-pregnancy normal-weight BMI</b> ( $\chi^2 = 4.688$ ; $p = 0.030$ ).
®Robertson Blackmore <sup>2</sup> (2016) (N = 171) US	Examine the relationship between exposure of intimate partner violence (IPV) and proinflammatory cytokine levels, a candidate mechanism accounting for poor psychiatric and obstetric outcomes, across the perinatal period	Prospective <sup>4</sup>	B, S	Lifetime exposure to IPV was associated with a range of psychiatric conditions, including generalized anxiety disorder, post-traumatic stress disorder, and depression. Further, IPV was associated with experiencing depression during both pregnancy and postpartum. Those with a history of IPV had $\uparrow$ levels of TNF- $\alpha$ (z = -2.29, p < 0.05) compared to those with no IPV exposure. After controlling for participants characteristics, a greater change in the levels of IL-6 during pregnancy compared to the postpartum period remained ( $\beta = 0.21$ , p = 0.04). This trend was different according to IPV status. Those who experienced violence had smaller changes in IL-6 across the time points compared to those not exposed to violence ( $\beta = -0.36$ , p = 0.04). From 6 weeks to 6-month PP, those exposed to violence had a greater $\downarrow$ in IL-6 compared to those without exposure ( $\beta = 0.36$ , p = 0.04). The change in TNF- $\alpha$ levels at 32 weeks' gestation to 6 weeks PP was $\uparrow$ than the change from 6 weeks to 6 months PP ( $\beta = 1.54$ , p < 0.01).
Fasching (2012) (N = 361) <i>Germany</i>	Identify trajectories of perinatal depressive symptoms and their predictors among low- income South African women who were already at risk of depression during pregnancy.	Prospective <sup>3</sup>	В	Haplotype block analysis showed that 10 of the 14 haplotypes of the <i>THP2</i> gene were assembled in three haplotype blocks (B1-B3). <b>SNPs rs6582071</b> and <b>rs11178997</b> (haplotype A) were also analyzed given these SNPs are known to be of functional relevance. <i>Genotype-phenotype association in haplotype Block A:</i> The most common haplotype was <b>GT</b> ( $63.4\%$ <i>homozygous for this haplotype and 31.6% had one allele</i> <i>for GT</i> ). The extremely rare haplotype GA (only one carrier) was excluded. The <i>linear mixed model</i> indicated an effect for <b>time</b> ( $p < 0.00001$ , <i>F-test</i> ) as well as haplotype <b>GT</b> ( $p = 0.02$ , <i>F-</i> <i>test</i> ) and the <b>interaction of time and haplotype GT</b> ( $p = 0.03$ , <i>F-test</i> ). <i>Pairwise comparison</i> demonstrated $\uparrow$ depression scores at different timepoints: 1) time point 3 for those <b>non-</b> <b>carriers of the GT</b> haplotype compared to those carrying <b>one copy of GT</b> at time point 3 ( $p < 0.01$ ). At timepoints 1 and 3, those <b>non-carriers of the GT haplotype</b> showed $\uparrow$ depression scores than those carrying <b>two copies of the</b> <b>GT</b> ( $p = 0.01$ ; $p = 0.01$ ). $\uparrow$ depression scores were found at <u>timepoint 1</u> compared to <u>timepoint 2</u> in all three haplotype groups ( <b>0 GT</b> : $p < 0.001$ , <b>1 GT</b> : $p < 0.01$ , <b>2</b> <b>GT</b> : $p < 0.00001$ ). There was an $\uparrow$ in depression scores from <b>timepoint 2</b> to <b>timepoint 3</b> for <b>non-carriers of a</b> <b>GT haplotype</b> ( $p = 0.01$ ) and for carriers of <b>two copies of</b> <b>a</b> <b>GT haplotype</b> ( $p = 0.01$ ) and for carriers of <b>two copies of</b>

				Haplotype block B1:SNPs: rs6582071, rs11178997, rs1117899; Haplotypes:CAT, CGA, CGT, TAAResults are identical to those from haplotype block A described above.Haplotype block B3:Block B3 resulted in four haplotypes (GAA, TAA, TA, TTG) with the most common being TTA. 33% of those carrying two copies and 51.8%^ carrying one copy.Linear mixed model:Those carrying two copies of TAA (0.6%) were joined with the carriers of one copy of TAA (15.5%). An effect for time was shown ( $p < 0.00001$ , F- test) as well as the interaction between TAA and time ( $p$ = 0.01, F-test). Differences between the patient groups at time 1 were seen for TAA, and both genotype groups were different between all three time points ( $p < 0.00001$ , $p < 0.0001$ , $p < 0.01$ ).Pairwise comparison: Three timepoints showed $\uparrow$ depression scores was seen in both groups ( $0$ TAA: $p =$ $0.03$ , $1 + 2$ TAA: $p < 0.0001$ . At time 2 and 3, an $\uparrow$ in depression scores was seen in both groups ( $0$ TAA: $p =$ $0.03$ , $1 + 2$ TAA: $p = 0.02$ , and depression scores were ower at time 1 compared to time 3 ( $0$ TAA: $p < 0.01$ , $1 + 2$ TAA: $p < 0.01$ .SNPs outside of haplotype blocks: rs10879354 (T/T + T/C vs C/C) showed an effect for time ( $p < 0.00001$ ) and SNP ( $p = 0.04$ ) but not for interaction.Pairwise comparison of the three timepoints showed $\uparrow$ depression scores at time 1 compared to time 2 ( $p < 0.00001$ ); time 2 compared to time 3 indicated a depression score $\uparrow$ ( $p < 0.001$ ); time 2 compared to time 3 indicated a depression score $\uparrow$ ( $p < 0.001$ ); time 3 was $\uparrow$ than time 1 ( $p < 0.01$ ).
				Six SNPs ( <b>T-703G</b> , <b>T-473A</b> , <b>A90G</b> , <b>C2755A</b> , <b>C10662T</b> , <b>G93329A</b> ) were noted from the <i>TPH2</i> gene. Two SNPs were found in the cases ( <i>T-473A</i> , $p = 0.042$ ;
Lin <sup>2</sup> (2009) (N = 200) <i>Taiwan</i>	To determine whether cytokines and kynurenine metabolites can predict the development of depression in pregnancy.	Cross- sectional <sup>1</sup>	В	<b>A90G</b> , $p = 0.038$ ) that were not found in <u>controls</u> . <i>Risk analysis</i> showed that the " <b>A</b> " allele conferred a risk ( $RR = 1.73$ ; 95% CI: 1.59-1.88) and demonstrated a dominant gene effect ( <i>A-allele carrier vs non-A allele</i> <i>carrier</i> , <i>AC vs CC</i> ; $p = 0.038$ ). A strong linkage disequilibrium in the 5' region between <b>SNPs -703A</b> and <b>A90G</b> in both groups ( <i>D' ranged from</i> 0.87 to 1) and the <i>D'</i> dropped as the distance between the pairs of markers $\uparrow$ ( <i>D' ranged from</i> 0.50-0.76). The <b>GTAA haplotype</b> , which contains the risk <b>2755A</b> <b>allele</b> , was different among <u>patients</u> and <u>controls</u> ( <i>Fisher's</i> <i>exact test</i> , $p = 0.044$ ); however, the significant in distribution of the <b>GTAA haplotypes</b> disappeared in a rigid permutation test ( $p = 0.086$ ).
Murakami2(2008)(N = 865)Japan	To examine the association between dietary GI and glycemic load (GL)	Prospective <sup>2</sup>	Bh	Compared with <b>dietary glycemic index (GI)</b> in the <u>first</u> <u>quartile</u> , <b>dietary GI</b> in <u>the third quartile</u> , but not the <u>fourth</u> was <i>associated</i> with $\checkmark$ risk of <u>PP</u> depression. <i>Multivariate</i> <i>ORs</i> (95% Cis) for <u>PP</u> depression for each of the <u>four</u> <u>quartiles</u> were: 1.00 (reference), 0.68 (0.39-1.17), 0.56

	and postpartum depression. $(0.32-0.995, p = 0.048)$ , and $0.72$ $(0.41-1.26)$ , respectively (p for trend = 0.18).
171 172 173 174 175	Author <sup>2</sup> = secondary analysis; Design <sup>#</sup> = Design + Number of timepoints investigated; Domain of factors investigated in relation to depression: $B = Biological$ , $Bh = Behavioral$ , $E = Environmental$ , $S = Social$ ; <i>Values (when provided)</i> = statistical values respective to analysis; Factors investigated in relation to depression <b>bold;</b> Timeframe and/or groups investigated <u>underlined.</u> (B) Study reported race/ethnicity
176	Of the 25 articles included in the final review, 80% of the articles were published in 2011 or later
177	[30–49]. Though the US maternal mortality rates continue to markedly exceed that of other high-income
178	countries [50], over half (60%) of the studies [31-34,36, 39-41, 45-48, 51-53] were conducted outside
179	of the US. Overall, sample sizes ranged from 16 to $3,252$ (N = $9,481$ ). Notably, sample sizes were much
180	lower in studies conducted in the US (n = 1,407, M = 141, SD = 127) [30, 35, 37, 38, 42–44, 49, 54, 55]
181	compared to non-US based studies (n = 8,074, M = 538, SD = 872.4) [31–34, 36, 39–41, 45–48, 51–53].
182	To determine if the difference was statistically significant, a Mann-Whitney U Test was performed using
183	the open-source software tool R v.2022.12.0+353 but did not demonstrate a statistically significant
184	difference (U = 50, $p = 0.1775$ ). However, the observable difference in sample sizes causes pause for
185	concern related to studies being sufficiently powered and potential limitations of existing evidence.
186	Thus, we deemed these findings to warrant further investigation to better understand implications and
187	possible explanations for the evident difference.

### 188 Upstream considerations for maternal mental health science

A total of four [33, 42–44] of the 25 studies discuss conducting an *a prior* power analysis to calculate the needed sample size with half of those being US based studies [37, 42]. However, of the two US based studies reporting a power analysis, one [37] does not report the calculated sample size nor if the study was sufficiently powered. Though power analysis was only reported in 16% of the 25 total studies, over half (60%) [32, 34–38, 40, 41, 43, 46, 48, 49, 52, 53, 54] note a small sample size as a study limitation. The percentage of US versus non-US based studies reporting sample size as a study limitation was equal at 60% each. Given a majority of the studies do not discuss power and 60% of the

total included studies note a small sample size as a study limitation, all interpretations for subsequentfindings should be interpreted with caution.

198 We suspected secondary use of data from government or publicly available datasets with large 199 sample sizes would explain the difference in sample sizes between US versus non-US based studies. Though nearly half of the studies were secondary analysis (48%) [38, 40, 41, 43–47, 49, 50, 53, 57], no 200 201 studies explicitly reported the use of government or publicly available datasets. Secondary analyses 202 accounted for 50% of the US based studies (50%) [40, 44, 47, 50, 57] versus 46.7% of non-US based 203 studies [38, 41, 43, 45, 46, 49, 53]. Given our secondary analysis assumption was false, we investigated 204 if differences in sources of research funding may account for differences in sample sizes as sources of funding may impact study budgets. Of the 20 studies [33–35, 37, 38, 40–43, 45–54, 57] that reported 205 sources of funding, eight were from the US [33, 40, 42, 47, 50–52, 57] and 12 [34, 35, 37, 38, 41, 43, 206 207 45, 46, 48, 49, 53, 54] were non-US based studies. Of the eight in the US, seven studies [33, 40, 42, 47, 50, 52, 57] were federally funded whereas 9 non-US based studies [37, 41, 43, 45, 46, 48, 49, 53, 54] 208 209 reported support from federal funding. Such findings suggest that though non-US based funding is slightly more diverse than US based funding sources, as expected, federal funding accounts for a 210 majority of US and non-US based research. 211

Since federal funding sources (e.g., National Institutes of Health [NIH]) are among the largest sources of research funding, these findings prompted us to evaluate the scope of federal funding allocated to maternal depression research. It is important to note that an in-depth analysis respective to research funding budgets is beyond the scope of the present review and here we report the number of publications coming from federally funded projects and the number of federally funded projects to date on maternal depression. We used NIH RePORTER to approximate the number of publications funded by NIH projects on "maternal depression" to compare US versus non-US based research

(reporter.nih.gov). Steps for this process can be seen in Fig 2. The initial search yielded 36,425 219 220 publications supported by 906 core projects (ranging from 1985 to 2023). Once duplicate publications and publications not specific to maternal depression were removed (i.e., infant outcomes, other non-221 perinatal population outcomes), only 136 (0.37%) US based publications under 93 (10.3%) core projects 222 (1991-2022) and 131 (0.36%) non-US based publications under 99 (10.9%) core projects (2002-2022) 223 224 remained from the initial search total of 36,425 publications and 906 core projects. These findings suggest there is not a substantial difference by country in the number of publications or core projects 225 related to maternal depression, and that the amount of funding allocated to maternal depression research 226 227 may be overinflated once accounting for funding that does not have maternal outcomes as a primary focus. For this reason, we also examined the project funding data from NIH RePORTER, irrespective of 228 country and publication, to understand how many maternal depression focused projects have been 229 230 federally funded to date. A total of 3,488 project results from 1985-2023 were returned for "maternal depression." However, similar to publications, once duplicate projects were accounted for and projects 231 with primary outcomes on persons other than perinatal persons were removed, only 158 projects (4.5%) 232 spanning over 38 years remained. Of the 158 projects, 92 (58.2%) were intervention studies. Further, a 233 number of southern states have some of the highest maternal mortality rates and/or poor maternal mental 234 235 health outcomes yet were among the lowest funded states for investigations on maternal depression (e.g., Louisiana (0), Arkansas (0), Mississippi (0), New Mexico (0), Kentucky (1), Texas (4)) [1, 8, 58-236 60]. 237

238

#### Fig 2. Steps for NIH RePORTER data acquisition

These findings establish the first federally funded project in the US on perinatal depression
began 38 years ago indicating perinatal mental health is a relatively new area of investigation, yet
temporal trends in funding appear to be partial to intervention-based studies. Further, scientists appear to

be largely relying on secondary use of data to generate new knowledge which inevitably limits study 242 design and methodological decisions. Though further investigation is warranted, the use of secondary 243 data may be a product of budget limitations specific to maternal mental health focused research and 244 consequently result in inadequately powered studies that challenge advancements in maternal mental 245 health science and care. The rising maternal mortality and morbidity rates and evidence of perinatal 246 247 depression having short-term and long-term health consequences for the offspring and familial unit positions maternal mental health as a public health issue. Given every person develops within a maternal 248 environment for up to 9.5 months, it is imperative that maternal mental health gains recognition as a 249 250 public health issue and sources of funding begin to prioritize maternal mental health science and care, especially in those states with higher disease burden and mortality rates. Collectively, these findings 251 may partly explain why knowledge gaps persist and health disparity gaps continue to widen. 252

## 253 **Participant characteristics**

Of the 21 studies [33, 35–38, 40-45, 47-50] that reported sample age (88%), the mean age of 254 255 participants was 29.49 (2.71) years. Race and/or ethnicity was reported in nine [36, 40, 42, 44, 48, 50– 256 52, 57] of the 25 studies (36%), but only five studies [40, 44, 50, 51, 57] (20%) included race/ethnicity 257 in the analyses. Further, eight [36, 40, 42, 44 50–52, 57] of the nine studies that reported race/ethnicity 258 were studies conducted within the US and 66.7% of those studies [40, 42, 44, 51, 52, 57] had samples 259 comprised predominantly of Non-Hispanic White individuals. Meaning, existing knowledge on 260 determinants of perinatal depression may exclude minority populations which have the highest rates of 261 perinatal depression and maternal mortality and morbidity rates in the US [1,11, 58–60]. Of the 15 studies [35, 36, 40–42, 44–46, 48–53, 55, 57] that reported participant education, 80% [35, 40, 42, 44, 262 45, 49–53, 55, 57] had samples primarily comprised of individuals with at least some college education. 263 Nine studies [36, 38, 40, 41, 44, 45, 48, 49, 52] reported income and/or SES with 88.8% [36, 38, 40, 41, 264

44, 45, 49, 52] including a significant number (i.e., ≥50% of total sample) of participants from low to
middle class. Nearly half (44%) of the studies [36, 38, 39, 45, 49–52, 55–57] reported parity with only
one study [49] specifically looking at first-time mothers.

268 These demographic factors are important to consider because current evidence suggests those from lower SES and/or first-time mothers may be at increased risk of developing perinatal depression; 269 270 however, there is conflicting evidence for education being a risk factor versus a protective factor. 271 Demographic information is collected routinely at prenatal visits, and though largely un-modifiable, may 272 aid in detecting risk and providing evidence for clinical decisions on who warrants prenatal depression 273 screening to temporally monitor symptoms and the need for intervention. Therefore, future studies may want to examine how different prenatal cohort demographics in clinical settings serve as predictors of 274 275 postpartum depression (PPD). Such investigations hold potential to leverage the use of existing data 276 with large sample sizes to inform how routinely collected clinical data can be aggregated and translated into mechanisms for perinatal depression risk screening and provide evidence to inform clinical 277 278 decisions in who to screen during pregnancy.

The support of a partner is commonly suggested to be a protective factor for perinatal depression, 279 yet partner status was only reported in eight (32%) [33, 36, 44, 45, 49, 50, 52, 53] of the 25 studies. 280 Further, three studies [36, 50, 52] had at least half of the sample comprised of single individuals, and 281 five studies [44, 45, 50, 53] controlled for partner status in the analyses. Interestingly, only two studies 282 [38, 49] reported the mode of delivery (8%), and four studies (16%) [37, 38, 47, 56] reported 283 breastfeeding status. In the US, the overall cesarean delivery rate increased by 60% from 1996-2009 284 (20.7% to 32.9%), and then experienced a slight decline in 2019 (31.7%) before increasing again in 285 286 2020 (31.8%) and 2021 (32.1%) [61]. Though the COVID-19 pandemic may explain the most recent increase in cesarean deliveries, growing evidence indicates there are psychological consequences 287

associated with cesarean deliveries, especially in the context of emergency cesarean deliveries [61] and for Black/African American delivering persons [62]. Regarding breastfeeding status, the direction and association of breastfeeding and perinatal depression has been controversial as some studies indicate breastfeeding as a protective factor [63]. Conversely, it has been indicated that perinatal depression may result in early cessation or that difficulties with breastfeeding may contribute to perinatal depression symptoms. Thus, mode of delivery and breastfeeding status may be important variables to consider in future investigations given the potential for psychological implications.

# 295 Methodological factors

There were 9 prospective cohort studies [39, 41, 46, 48, 50–52, 54, 57], eight cross-sectional 296 studies [34, 36, 38, 40, 43–45, 47], and six case-control studies [33, 35, 37, 49, 53, 56]. There was also 297 298 one pilot study [42] and one randomized control trial [55]. The most common types of analytic methods applied were those looking at group differences (92%), correlations (52%), and regression (36%) while 299 300 more complex forms of analyses, such as, mixed effects modeling (8%) and path analysis (2%) were the least common. All studies conducting biospecimen collection [33-40, 42, 43, 47-52, 54, 56, 57, 64] 301 provided methods for processing and analyzing of the samples, though the level of detail provided was 302 303 variable. All biospecimen samples were blood except for three studies that also collected either saliva [48], fecal [42], or urine [57] samples in addition to blood samples. A total of six [33, 35, 36, 50, 52, 56] 304 305 studies reported the time of biospecimen collection, and one study reported requiring fasting (12 hours) when collecting blood samples [35]. 306

Though not unexpected, the Edinburgh Postnatal Depression Scale (EPDS) was the most used instrument to measure depression (60%) [33, 35, 37–39, 42, 46–49, 51, 52, 54, 56, 57] followed by the Center for Epidemiological Studies Depression (CES-D) (16%) [36, 40, 44, 55]. Only 20% of the

310	studies [41-43, 50, 53] utilized semi-structured interviews to measure depression for purposes other than
311	group allocation (i.e., depressive, control) and/or study eligibility. Of the 15 studies using EPDS to
312	measure depression, 40% did not report a specified cut-off score [39, 42, 47, 49, 51, 57]. The nine
313	studies [33, 35, 37, 38, 46, 48, 52, 54, 56] reporting EPDS cut-off scores varied between 9-13. The most
314	common cut-off score was 10 (33.3%) [38, 48, 56], which is lower than the current clinically
315	recommended cut-off score of $\geq$ 13 [66]. Of the seven studies [35, 37, 38, 46, 48, 54, 56] using an EPDS
316	cut-off score other than $\geq$ 13, only three studies (28.6%) [35, 37, 46] provided scientifically supported
317	rationales for using an alternative cut-off score. The US Preventive Services Task Force indicated 10
318	and 13 as the most common cut-off scores used [10]. A recent individual participant data meta-analysis
319	suggested that using a cut-off score of $\geq 11$ may be preferable due to combined sensitivity and
320	specificity being maximized [67, 68]. However, the current recommendation of $\geq$ 13 has remained
321	unchanged since it was developed by Cox and colleagues (1987) nearly four decades ago in a
322	postpartum sample in the United Kingdom.

As determined by quality appraisal assessments, concerns for risk of bias were noted or were 323 unclear related to the following types of bias: 13 (52%) selection bias, 3 (12%) recall bias, and 24 (96%) 324 measurement bias. Fig 3. A narrative description of risk of bias considerations for each included article 325 is detailed in **S1 Table**. Moderate level of risk was noted in six studies for selection bias [35, 40, 41, 43, 326 45, 47], one for recall bias [40], and zero for measurement bias, whereas high level of risk was noted in 327 two studies for selection bias [44, 46], two for recall bias [53, 57], and two for measurement bias [49, 328 329 53]. Further, a majority of the studies (88%) were indicated as having an unclear risk of bias for measurement bias largely due to studies not providing sufficient information or references to support the 330 use of the measurement with respect to their sample characteristics and/or cut-off scores. For instance, 331 332 Sha and colleagues (2022) conducted a study in a non-Swedish sample (US based sample) but

referenced a study validating the Swedish version of the EPDS in pregnancy. Another example is that of
Miller and colleagues (2018) who used CESD to measure perinatal depression, and their supporting
reference was a study assessing the efficacy of the instrument for use as screener for depression in
community residing older adults (50-96 years of age).

- **Fig 3. Summary of level of risk of bias per study.** <sup>a</sup>US based study.
- 338

339 Further, it is important to note the items comprising the EPDS were adopted from existing scales mainly developed in the United Kingdom (UK) in non-perinatal populations of variable age (16-65) [66, 340 341 69–71]. The sample characteristics described by Cox and colleagues (1987) are is incongruent with all 342 15 studies that reported using the EPDS. A total of 10 (66.7%) studies [33, 37, 41, 42, 46–51] cite Cox 343 and colleagues (1987) with 60% of these studies [33, 37, 42, 49–51] using this reference to substantiate 344 the validity and reliability of the instrument and/or cut-off score for use in their study though there are notable differences in sample characteristics (i.e., country, mode of delivery, social class, relationship 345 status, language). Though the EPDS is currently considered "gold standard" for measuring perinatal 346 depression, increased inclusion of supporting references and/or scientifically supported rationales may 347 be particularly useful to aid in decreasing variability in cut-off scores by collectively establishing best 348 practices for determining cut-off scores respective to sample characteristics. 349

#### 350 Methodological considerations

As evidenced by the findings in this review, insufficient evidence is being provided for instrument selection in measuring perinatal depression. Without robust measures for primary outcome or group allocation variables, the risk of compromising the integrity of subsequent findings and the wider body of evidence is high. Though the instrument has remained unchanged in nearly four decades, social and political norms for child-bearing persons and marginalized groups have evolved since instrument

356 inception in the 1980's. Therefore, while it is common knowledge amongst maternal mental health 357 scientists that the EPDS or CESD are widely used to assess perinatal depression, it is important the scientific community stay diligent in questioning the utility of instruments, especially when being used 358 in diverse samples. Thus, the psychometric properties of the instrument continually need to be critically 359 360 examined and it is important that supporting literature that is applicable to the present sample be 361 referenced as to generate evidence for instrument validity and reliability across diverse samples, to establish best practices, and indicate when modifications and/or the development of new measures may 362 be warranted. 363

364 Given the variability in cut-off scores and evidence suggesting perinatal depression may phenotypically differ between pregnancy and postpartum as well as from that of non-reproductive 365 366 depression [73, 74], it is important for future investigations to consider the utility of existing perinatal depression measures for present day use. Such endeavors will aid in determining if and what 367 modifications may be warranted to improve the scientific and clinical utility of perinatal depression 368 369 measures. While we acknowledge the limitations of incorporating clinical interviews as a form of data collection (e.g., time constraints, burdensome to participants/staff, training, internal validity concerns), 370 371 future investigations may be strengthened by conducting semi-structured interviews in addition to self-372 report measures when measuring perinatal depression. Incorporating two forms of measurement that 373 yield two types of data (i.e., qualitative, quantitative) will not only strengthen any subsequent findings, 374 but may also be particularly useful to progress our understanding of depression symptoms exclusive to 375 perinatal populations and lead to advancements in life-stage informed measures that can increase precision in detection and timely intervention. 376

The bioavailability of essential amino acids (e.g., tryptophan, competitor amino acids), the
precursors to a number of neurotransmitters commonly associated with psychiatric conditions, depends

379 on dietary intake. Thus, biospecimen collection respective to timing of food consumption is likely important to consider in investigations including essential amino acids and its metabolites as levels may 380 significantly vary depending on when sample collection takes place. Yet no studies reported 381 biospecimen collection time in relation to timing of food consumption suggesting this is not common 382 practice. Free (non-albumin bound) tryptophan (TRP) is what can be transported across the blood-brain-383 384 barrier (BBB) to make it available in the brain for serotonin synthesis [22]. Conversely, it has been suggested that TRP has a higher affinity for the BBB than for albumin, and albumin bound TRP close to 385 the BBB may separate from albumin to then transport across the BBB. Meaning, measurement of both 386 387 free and total TRP is likely important in the study of psychiatric conditions, but only one study [34] specified if free and/or total TRP was measured. For these reasons, it is important for future 388 investigations including essential amino acids to 1) consider biospecimen collection times in relation to 389 timing of food consumption to advance our understanding of tryptophan metabolism in the perinatal 390 period and 2) to clarify if free and/or total TRP is being measured as such considerations are essential 391 for making meaningful interpretations of the findings. 392

Lastly, each type of biospecimen and method for processing and analyzing of samples introduces 393 bias innate to the specified type and method [65]. Therefore, decisions on what type of biospecimen(s) 394 395 to collect and methods of analysis warrant thoughtful consideration. As evidenced by the articles included in this review, there is a need for increased transparency in reporting of methods and rationales 396 397 to support such methods. Transparency is vital not only for the purposes of reproducibility but also to 398 collectively establish best practices for methods of biological sample selection, collection, processing, and analysis. Overall, these findings suggest that methods of investigation in maternal mental health 399 science have room for improvement and can be strengthened with increased attention and reporting of 400 401 sufficiently supported methodological decisions and processes, such as those discussed in this review.

By strengthening the methods of investigation in maternal mental health science, we can progress
standards for best practices as well as mitigate the risk of generating conflicting findings that are a result
of unsound methods rather than true conflicting findings.

## 405 **Biological determinants**

A total of 20 studies [33–40, 42–44, 47–52, 54, 56, 57] investigated biological determinants of perinatal depression. Inflammatory markers were investigated in 10 studies [33, 35, 36, 40, 44, 48, 50– 52, 57], tryptophan and/or tryptophan metabolites in seven studies [33, 34, 42, 49, 52, 54, 56], genetic polymorphisms in three studies [37, 39, 43], micronutrient alterations in two studies [35, 38], and neurological factors in one [47], respectively.

### 411 Inflammatory markers and oxidative stress

TNF- $\alpha$  (pro-inflammatory cytokine) was positively correlated with prenatal depression and those 412 with prenatal depression had higher TNF- $\alpha$  levels compared to those without [35, 44]. Miller and 413 colleagues (2018) found that even when controlling for sociodemographic factors, those with prenatal 414 depression unresponsive to antidepressant treatment and those with untreated prenatal depression had 415 higher TNF-  $\alpha$  levels compared to those with prenatal depression that responded to antidepressant 416 treatment. These findings suggest that TNF- $\alpha$  may be a useful biomarker for determining a subtype of 417 perinatal depression that is treatment resistant to antidepressants. However, it is important to note Miller 418 419 and colleagues (2018) do not specify specific antidepressants used for treatment nor the duration of treatment. Additionally, intimate partner violence is commonly indicated as a risk factor for perinatal 420 421 depression. Robertson-Blackmore and colleagues (2016) found a history of intimate partner violence to 422 be positively associated with TNF- $\alpha$ . Also suggesting interpersonal relationships have potential to induce inflammatory responses, Ross and colleagues (2018) found romantic partner relationships low in 423

424	both negative (e.g., conflict) and positive (e.g., support, intimacy) features to be associated with lower
425	anti-inflammatory cytokines (IL-10, IL-13) and higher pro-inflammatory profile (IL-6:IL-10 ratio).
426	Whereas Finy and colleagues (2018) found past (i.e., childhood abuse) and current adversities (i.e.,
427	lower SES) to be positively associated with elevations in inflammatory markers (i.e., CRP, IL-6).
428	A positive association among depression symptoms and IL-6 (involved in both immune response
429	and inflammation) was found [40, 48] and even when controlling for pre-pregnancy body mass index
430	(BMI), higher depression scores were positively associated with both IL-6 and TNF- $\alpha$ [36]. Similarly,
431	Achytes and colleagues (2020) found, even after adjusting for demographic factors and pharmacological
432	treatment, that postpartum individuals with elevated plasma levels of IL-6, IL-8 (pro-inflammatory
433	cytokine), and TNF- $\alpha$ (modest) had increased odds of PPD, while a decrease in IL-2 (pro-inflammatory
434	cytokine) increased the odds of PPD. Plasma IL-10 (anti-inflammatory cytokine) and IL-1 $\beta$ (pro-
435	inflammatory cytokine) were not associated with increased risk for PPD. Results from Sha and
436	colleagues (2022) support the aforesaid findings specific to IL-6 but not for IL-1 $\beta$ . Moreover, IL-1 $\beta$ was
437	found to be negatively associated with depression scores across four-time points (i.e., three trimesters,
438	one postpartum time point). Findings from Sha and colleagues (2022) also suggest a potential second-
439	trimester biomarker panel (IL-6, TNF-α, quinolinic, and kynurenine) to predict PPD. Conversely,
440	Christian and colleagues (2009) found that depression scores were positively correlated with IL-2 and
441	IL-10, and Robertson-Blackmore and colleagues (2016) did not find depressive symptoms at 32 weeks'
442	gestation to be associated with IL-6 or TNF- $\alpha$ . Differences in perinatal timepoints assessed and
443	methodological decisions may explain conflicting results.
444	Across the pregnancy period depression was positively associated with oxidative stress, as

Across the pregnancy period depression was positively associated with oxidative stress, as measured by 8-isoprostane (considered a stable biomarker of oxidative stress) in urine, and oxidative stress mediated the relationship between prenatal depression and spontaneous preterm birth [57]. While

sources of oxidative stress vary, evidence suggests the sources are largely related to environmental and
lifestyle factors. Therefore, it may be meaningful to investigate factors that influence oxidative stress in
the perinatal period in relation to associated health outcomes (i.e., depression, spontaneous preterm
birth) to explore how such factors may be attenuated and leveraged for risk mitigation.

### 451 *Tryptophan pathway, metabolites, and neurotransmitters*

Brain TRP availability was negatively associated with plasma competitor amino acid 452 concentrations during the postpartum period (+77% isoleucine, +55% leucine, +52% tyrosine) and the 453 454 intensity of postpartum "blues" [34]. It is important to note that though we acknowledge postpartum blues as different than PPD, the difference is largely the duration of symptoms as postpartum blues is 455 considered transient. The timepoint investigated by Bailara and colleagues (2006) was three days 456 postpartum, meaning it is unknown if these symptoms were in fact transient or if symptoms continued 457 beyond study participation and were later considered PPD. Therefore, for transparency, we retained the 458 459 use of the term postpartum blues and decided to include these findings given the findings are consistent with those in non-perinatal populations yet is understudied in perinatal populations [22, 79]. 460

461 Plasma levels of serotonin and neuropeptide Y (stimulates food intake, particularly 462 carbohydrates) were lower in those with PPD [49]. Conversely, dopamine (role in movement, 463 motivation, pleasure) and norepinephrine (role in flight-or-fight response) were higher in those with 464 PPD compared to controls. Achytes and colleagues (2020) also found that lower plasma serotonin increased the risk of PPD, whereas absolute plasma levels of TRP did not affect the risk of PPD. Though 465 466 not specific to depression, Achytes and colleagues (2020) also found that suicide, a distal outcome of 467 depression and a leading cause of maternal mortality, was associated with lower levels of plasma serotonin and lower plasma serotonin increased the odds of a completed suicide attempt during 468

pregnancy even when adjusting for EPDS scores. Though such findings require further investigation,
serotonin may be significant biomarker of suicide risk in perinatal populations.

Prenatally, plasma levels of kynurenine (KYN) and kynurenic acid (KA) were significantly 471 472 higher in the depressed group compared to the non-depressed group. Postpartum, higher plasma levels of KYN, KA, and KYN/TRP and KYN/KA ratios were observed in the PPD group compared to those in 473 474 the non-depressed group [54]. Sha and colleagues (2022) found quinolinic acid, a neurotoxic TRP 475 metabolite that gets synthesized via the KYN pathway, to be associated with depression in the third 476 trimester. Higher plasma levels of quinolinic acid were associated with both increased severity and risk 477 of falling into a category of clinically significant symptoms (i.e., EPDS  $\geq 13$ ). In non-perinatal populations with depression, inflammation is suggested to play a role in the shunting of TRP down the 478 479 KYN pathway and KYN has become increasingly recognized as a potential link between inflammation and depression [22, 80]. KYN has also been linked with sleep disturbances, a common depression 480 symptom, which is also commonly experienced perinatally [80, 81]. Poor sleep has also been widely 481 482 established as a risk factor for a number of chronic health conditions. For these reasons, it may be beneficial for future research to explore such interactions and the directionality of said interactions as 483 they relate to perinatal depression onset, chronicity, and risk for comorbidities. 484

Conversely, Veen and colleagues (2016) found KYN to be significantly lower in patients with perinatal depression compared to non-depressed controls. Similarly, findings from Nazzari and colleagues (2020) suggest a negative association among prenatal KYN levels and depression symptoms in late pregnancy and postpartum after adjusting for maternal age. No differences were found in the plasma levels of TRP or its metabolites among perinatal depressed groups compared to non-depressed controls [54, 56]. Kimmel and colleagues (2022) found no significant associations among TRP/serotonin related metabolites or bile acids and depression. While three studies [42, 48, 56] provided conflicting

results related to KYN levels, differences in the timepoints assessed, the country where the study took 492 place, and differences in methodological decisions may explain the conflicting results as lifestyle 493 choices and psychosocial and environmental factors are likely quite different between countries. Two of 494 the three studies [42, 56] were also likely underpowered as one was a pilot study with a sample size of 495 496 30 and the second had a sample size of 42, with 23 being cases of PPD while the remaining were 497 controls. Lastly, as previously discussed, sleep disturbances have been linked to the KYN pathway and depression, and inflammation is suggested to increase the shunting of TRP down the kynurenine 498 pathway. However, five of the seven studies examining TRP did not consider inflammation as a variable 499 500 in their study nor did any of the seven studies assess sleep. Inflammation and sleep disturbances are both commonly experienced perinatally which may explain why these factors have been overlooked; 501 502 however, for the reasons discussed, they are important factors to consider in the context of perinatal 503 depression.

### 504 Genetic Polymorphisms

Catechol-O-methyltransferase (COMT) is a gene that provides instruction for the metabolization 505 of catecholamine neurotransmitters (i.e., epinephrine, norepinephrine, dopamine). A common functional 506 polymorphism studied in relation to psychiatric conditions is the COMT variant, Val<sup>158</sup>Met (rs4680). 507 where an amino acid change of valine [val] to methionine [met] is suggested to reduce the activity of the 508 COMT enzyme that metabolizes the aforesaid neurotransmitters [82–84]. This polymorphism is 509 suggested to influence cognition and behavior in psychiatric conditions, such as depression. Though the 510 COMT variant is minimally explored in perinatal depression, Comasco and colleagues (2011) found an 511 association among the polymorphism (COMT-Val<sup>158</sup>Met) and PPD symptoms at 6 weeks but not at 6 512 months. Additionally, genetic variation in the Monoamine oxidase A (MAOA) gene is suggested to 513 contribute to depression, specifically when MAOA activity is high. Higher gene activity occurs when 514

there is a polymorphism in rs1137070 where a C allele replaces a T. Higher MAOA activity induced by 515 516 this polymorphism may result in rapid catalyzation of the neurotransmitters serotonin and norepinephrine [85]. However, a meta-analysis suggests the T variant is associated with major 517 depression in non-pregnant populations [86]. With regard to gene-gene interactions, Comasco and 518 colleagues (2011) found COMT-MAOA interactions to be significantly associated with PPD symptoms. 519 520 For instance, among low MAOA carriers (T allele), the Met variant of the COMT gene was related to PPD symptoms; whereas the high MAOA variant (C allele) was related to PPD symptoms only when 521 combined with the Met allele of COMT. In terms of gene-environment interactions, COMT-Val<sup>158</sup>Met 522 523 was also associated with PPD symptoms when psychiatric history and stress were present. This interaction effect may explain why studies have reported significant associations of both MAOA 524 525 polymorphisms with depression.

Two studies explored polymorphisms of tryptophan hydroxylase 2 (TPH2), the rate limiting 526 enzyme of serotonin biosynthesis, in those with perinatal depression [39, 43]. The TPH2 gene plays a 527 major role in the regulation of the neurotransmitter serotonin, and genetic variants of TPH2 are 528 suggested to play a significant role in both susceptibility to depression and response to a commonly 529 530 prescribed treatment, selective serotonin reuptake inhibitors (SSRIs) [87, 88]. Lin and colleagues (2009) 531 found that the TPH2 C2755A polymorphism occurred only in those with perinatal depression and/or an anxiety disorder. Further, though significance faded after Bonferroni correction, a risk analysis 532 demonstrated that the TPH2 C2755A polymorphism increased risk of perinatal depression and exhibited 533 534 a dominant gene effect. However, it is important to note the reported study is specific to a Han Chinese population, and the authors position this polymorphism as a potential population specific indictor of 535 536 depression risk based these findings and current evidence in Han Chinese populations. Also exploring 537 TPH2 polymorphisms, Fasching and colleagues (2012) found the single-nucleotide polymorphism

(SNP) in intron 8 (rs10879354) to be the only SNP to show consistent effects across all time points ( $\geq$ 538 31 weeks gestation, 48-72 hours postpartum, 6-8 months postpartum) in a German population. Since 539 TPH2 polymorphisms influence the activity of neurotransmitters commonly associated with depression 540 in non-perinatal and perinatal populations [87, 88], it would be beneficial for future investigations to 541 further examine potential genetic biomarkers and their influence on relevant metabolic pathways. 542 543 Progressing this area of inquiry will not only improve the odds of discovering a genetic biomarker for perinatal depression risk but may also advance our understanding of population specific biomarkers 544 which could drastically increase precision in early detection and intervention. 545

#### 546 *Micronutrient alterations*

A negative association among vitamin B12, cobalamine deficiency (cB12), and serotonin were 547 observed with probable PPD [38]. Adequate amounts of B12 are suggested to be particularly important 548 in pregnancy for both the pregnant person as well as the offspring given its role in nervous system health 549 550 [89, 90]. Concurrent with folate, B12 aids in DNA synthesis as well as red blood cell production. Interestingly, dietary sources considered high in B12 (i.e., animal-based proteins) are also sources high 551 in TRP, the precursor to serotonin [91]. In the same study [38], a positive association was found among 552 553 Methylmalonic acid (MMA) (suggested marker of functional deficiency of vitamin B12), homocysteine (hcy) (broken down by B12 and folic acid; elevated levels suggest vitamin deficiency), and 5 554 methyltetrahydrofolic acid (5-methyl THF) (suggested marker of a folate/methyl trap due to existing 555 B12 deficiency) and depression symptoms. Further, elevated MMA and 5-methyl THF were found to be 556 significant predictors of probable PPD, and MMA was suggested to be a potential mediator of PPD. 557

558 Other micronutrient alterations that were associated with prenatal depression were total n-3 559 polyunsaturated fatty acids (n-3 PUFA), eicosapentaenoic acid (EPA), and docosahexaenoic acid

560 (DHA). EPA and DHA are two notably important fatty acids given they are critical for the development and function of the central nervous system in both perinatal persons and the developing fetus and have 561 anti-inflammatory properties [92]. Chang and colleagues (2018) found that those with prenatal 562 depression had lower levels of total n-3 PUFA, EPA, and DHA compared to those without prenatal 563 depression. Prenatal depression duration was negatively correlated with total n-3 PUFA, EPA, and 564 565 DHA. These findings indicate micronutrient deficiencies, either due to low dietary consumption and/or an existing functional deficiency, may be useful measures for detecting perinatal depression risk or early 566 symptom onset. Though supplementation of B12 has provided conflicting results, reviews and meta-567 568 analyses of RCTs have shown the fatty acids discussed can improve depression symptoms in perinatal and non-perinatal populations and may be useful as an independent or adjuvant treatment modality 569 570 depending on the individual [92–94]. This is particularly important to note for perinatal populations as 571 pharmacological interventions are not highly desired in pregnant or breastfeeding persons due to concerns for potential implications on the developing offspring [95, 96]. Thus, though future research is 572 needed, micronutrient supplementation may be desirable option for those at risk or those exhibiting mild 573 depressive symptoms during pregnancy to serve as form of risk mitigation and indirect health promotion 574 strategy for the developing offspring. 575

#### 576 Neurological alterations

Brain serotonin-1A (5HT1A) receptor binding potential, as measured by positron emission tomography (PET), suggested a 20-28% reduction in postsynaptic 5HT1A receptor binding in those experiencing PPD [47]. The most significant reductions were found to be in the anterior cingulate (related functions - emotional expression, attention, mood regulation) and mesiotemporal cortices which includes the amygdala (input and processing of emotion) and hippocampus (episodic memory). Likely due to methods of data acquisition and the unknown risks for perinatal individuals and their offspring,

investigations into neuroanatomical features and their respective roles in perinatal specific depression
are sparse. While there are some conflicting findings, the present findings are consistent with some
literature on depression and/or anxiety in non-perinatal populations [98, 99].

#### 586 Behavioral determinants

Six studies [33, 38, 41, 45, 46, 55] investigated behavioral determinants of perinatal depression.
Dietary intake was investigated in three studies [38, 45, 46] whereas suicide (i.e., attempts, ideation, risk)
was explored in two [33, 41]. Physical activity [55] and functional impairment [41] were each explored in
one.

Though specific to the third quartile (ascending quartiles per glycemic index/load), Murakami and 591 colleagues (2008) found higher dietary glycemic index (GI) decreased the risk of PPD, while no 592 593 associations were found between PPD and dietary glycemic load (GL). Lower milk, meat, and egg consumption during the postpartum period was associated with probable PPD [38]. Further, even after 594 adjusting for potential dietary and non-dietary confounding factors, higher tryptophan intake was 595 596 independently negatively associated with depressive symptoms in pregnancy [45]. TRP, the precursor to the neurotransmitter serotonin that is commonly associated with depression, is an essential amino acid. 597 598 Essential amino acids, such as TRP, are only made available through dietary intake as they are not independently produced by the body [22]. Though Dhiman and colleagues (2021) did not specifically 599 examine TRP, animal and plant-based proteins (i.e., milk, meat, eggs, spirulina, nuts and seeds) are among 600 some of the highest sources of TRP. Thus, together these findings indicate lower dietary consumption of 601 TTRP in the perinatal period may contribute to increased risk of depression onset which is consistent with 602 findings from animal and human studies in non-perinatal populations [19, 22, 73, 74]. Additionally, 603 604 though not a variable noted in any of the included studies, nausea and vomiting due to "morning sickness"

or hyperemesis gravidarum (severe type of morning sickness) occurs in roughly 70% of pregnancies.
Thus, these variables may be particularly important to consider in investigations of TRP metabolism
perinatally as these variables are likely to increase risk for depletion of essential nutrients vital for maternal
and fetal health.

Two studies independently demonstrated alcohol consumption [41] during pregnancy or a high 609 risk of suicide (i.e., current and past attempts and ideation) [33, 41] increased the odds of being classified 610 into the perinatal depression group. Those endorsing higher functional impairment had increased odds of 611 being classified in the perinatal depression group [41] whereas a single randomized control trial (RCT) 612 [55] demonstrated a prenatal physical exercise program to decrease the risk of PPD. The RCT consisted 613 614 of 60-minute sessions three times per week starting at 12-16 weeks gestation and found the percentage of people reporting depression was lower in the intervention group than in the control group at both 38 weeks 615 616 gestation and 6 weeks' postpartum. The findings related to substance abuse, history of suicide attempts or current suicidal ideation, and exercise are consistent with existing literature. Conversely, functional 617 impairment is a less commonly studied factor [75]. Functional impairment is a marked feature of clinical 618 depression yet is not routinely assessed, if at all, during the perinatal period. Exploring the implications 619 of functional impairment in the perinatal period may be particularly useful to clinically monitor for 620 621 declines from baseline functioning for those with and without pre-existing disabilities or functional 622 impairments. Further research in this area may help advance detection strategies for life-stage specific 623 onset or exacerbations of pre-existing functional impairment that may not otherwise be visible to clinicians 624 and provide evidence for identifying individuals in need of increased support. While we understand these 625 behavioral factors may increase the risk of PPD and behavioral interventions targeting such factors may 626 aid in mitigating risk, it is important to consider who is disproportionately impacted by perinatal

depression and the broader contextual factors that serve as potential barriers and are beyond the immediatecontrol of the individual (e.g., social determinants of health).

#### 629 Social and environmental determinants

A total of seven studies [36, 37, 40, 41, 50, 51, 53] investigated social and environmental
determinants of perinatal depression. Five studies investigated significant life events (e.g., trauma,
intimate partner violence, history of childhood abuse) [37, 40, 41, 50, 53] and social support [36, 37, 40,
41, 51]. Perceived stress was investigated in two studies [36, 37] and unhappiness with pregnancy [37]
and food insecurity [41] were investigated in one study.

Two commonly suggested risk factors of perinatal depression, psychiatric history [37] and 635 636 significant life events [37, 40, 41, 50, 53], were positively associated with perinatal depression [76, 77]. 637 Even after adjusting for sociodemographic factors, personal history of depression, and timing of depression onset, those reporting a history of childhood trauma were at higher risk of PPD, anxiety, and 638 639 suicide attempts than those without [53]. A dose effect was present between the number of childhood 640 trauma types and risk of PPD. Robertson-Blackmore and colleagues (2016) examined lifetime exposure to intimate partner violence and found lifetime intimate partner violence to increase the likelihood of 641 experiencing perinatal depression. For those currently endorsing frequent hostile and insensitive social 642 interactions experienced an increase in prenatal depressive symptoms [36]. Further, there was a negative 643 relationship among social support and depression symptoms, and low social support served as a 644 645 significant predictor of perinatal depressive symptoms [36, 41, 51]. Relatedly, higher negative qualities in one's interpersonal relationships were associated with greater depressed mood, perceived stress, and 646 pregnancy distress [51]. Collectively, these findings indicate the level of past exposure, type of 647 648 exposure, and current appraisal of interpersonal relationships may moderate one's level of risk for PPD.

Consistent with current evidence, perceived stress was positively correlated with perinatal 649 depression [36, 37, 40, 51]. Being unhappy about one's pregnancy was also positively correlated with 650 perinatal depression [36]. Such findings are particularly important to note for US based research given 651 the current political and social climate related to child-bearing age person's rights and abortion access. 652 653 Irrespective of one's personal views on the matter, the recent changes in federal and state level 654 regulations are likely to increase rates of perinatal depression and subsequently result in a surge of negative health outcomes in both perinatal persons and the offspring. Fox and Brod (2021) investigated 655 the cost of perinatal complications in the US for all 2019 births from conception to age 5 and found such 656 657 complications to result in \$32.2 billion in societal costs (i.e., healthcare expenses, loss of productivity, social support services) [78]. It was also suggested these estimates likely underrepresent the totality of 658 the financial burden. This analysis was conducted prior to federal and state level changes on abortion 659 660 access and a global pandemic. Despite spending more on healthcare than any other developed country, the US and its healthcare system have yet to gain control over the rising maternal mortality and 661 morbidity rates. Meaning the US is likely not prepared to manage a surge in perinatal health 662 complications, especially so soon after a global pandemic. Therefore, advancements in maternal mental 663 health care are vital for individual and systemic health. Future investigations to further examine 664 665 unhappiness with pregnancy as a potential risk factor as well as diligent monitoring of trends in 666 incidence since the change in regulations are necessary to generate evidence for increased resources and 667 support.

668 One study [41] found food insecurity to predict perinatal depression in two groups (i.e., prenatal 669 only depression, prenatal and postpartum depression) and the odds of experiencing depression both 670 prenatally and in the postpartum was 2.5 greater in the presence of food insecurity. Interestingly, non-671 perinatal specific research that began examining the impact of COVID-19 on food insecurity found food

insecurity to disproportionately impact racial and ethnic groups, and the states with the highest projected
food insecurity rates based on overall population occurred in states that also have some of the highest
maternal mortality rates (i.e., Louisiana, Texas) [76]. These findings suggest food insecurity as a
potential predictor of PPD and demonstrates the importance of post-pandemic science to consider the
remnant effects of global pandemics on perinatal health.

### 677 **Prospective interactions**

The specific factors explored across the four domains were highly variable. Therefore, this review does not claim to present an exhaustive description of all potential interactions that can be interpreted from findings of the aggregated factors. Due to patterns in which interactions with TRP and its metabolites emerged, we specifically chose to focus on these interactions as they may suggest a potential role in perinatal depression risk and onset.

Although minimally explored in perinatal populations, disruption in serotonin or the serotonergic 683 684 system is widely considered to contribute to depression onset, maintenance, and response to treatment (i.e., SSRIs) in non-perinatal populations [88, 98, 99]. Some evidence suggests the disruption of the 685 serotonergic system is more prominent in biologically born females compared to males, and that the 686 687 dysregulation of serotonin may partly explain why biologically born females experience depression at two times the rate of biologically born males. Given TRP is the precursor to serotonin, brain TRP 688 689 availability is vital for adequate production of the neurotransmitter serotonin. Other essential amino 690 acids (e.g., isoleucine, leucine, phenylalanine) compete with TRP to cross the BBB and are the 691 precursors to several other neurotransmitters (e.g., dopamine, norepinephrine) that are implicated in 692 psychiatric conditions [79, 100]. Consistent with current evidence indicating TRP competes with other essential amino acids to cross the BBB, Bailara and colleagues (2016) found a negative association 693

694	among brain TRP availability and competitor amino acid concentrations, notably one of which was
695	tyrosine, a precursor of dopamine and norepinephrine. Since essential amino acids (i.e., TRP, isoleucine,
696	leucine, phenylalanine) are not independently produced by the body and depend on dietary intake for
697	availability, dietary habits, food accessibility, and other factors that may influence changes in metabolic
698	activity (e.g., genetic polymorphisms, morning sickness, breastfeeding, comorbid conditions) are
699	particularly important to consider in this area of inquiry. A majority of the studies in this review
700	examining TRP and its metabolites did not concurrently examine or control for dietary habits,
701	micronutrients, and/or food accessibility; however, a majority of the studies that did examine such
702	factors independent of TRP found associations with PPD [35, 38, 41, 46].
703	The mechanisms underlying the increased uptake of TRP in the brain are not fully understood,
704	but some evidence suggests higher dietary carbohydrate intake can promote the uptake of TRP in the
705	brain resulting in increased serotonin [100, 101]. Interestingly, Rihua and colleagues (2018) found
706	plasma levels of serotonin and neuropeptide Y (stimulates food intake, particularly carbohydrates) [102,
707	103] to both be lower in those with PPD. Achytes and colleagues (2020) also found lower levels of
708	plasma serotonin to increase risk of PPD but did not denote increased risk of PPD related to plasma
709	TRP. However, they did note an elevated KYN/serotonin ratio was associated with an increased risk of
710	PPD. TRP degradation into KYN is suggested to increase in response to immune and inflammatory
711	activation in non-perinatal populations experiencing depression [19, 22, 104, 105]. Since pregnancy
712	naturally induces immune and inflammatory responses in the pregnant individual to accommodate the
713	developing fetus, TRP degradation into KYN may occur more often during this life-stage and increase
714	one's risk for depression. Veen and colleagues (2016) did not explore the aforesaid in the pregnancy
715	period, but they did find this to be the case in the physiological postpartum period.

716 Though the life-stage itself induces a unique immune and inflammatory response, additional 717 factors throughout the perinatal period, such as the social, environmental, and behavioral factors discussed in this review (e.g., stress, social support, intimate partner violence) may further promote 718 719 immune and inflammatory responses and increased TRP degradation down the KYN pathway 720 predisposing one to depression onset. Further, sleep disturbances are common perinatally and are often 721 attributed to "normal" pregnancy and postpartum symptoms, but sleep disturbances also happen to be a common symptom of depression and/or anxiety in non-perinatal populations. Though sleep disturbances 722 are linked to the TRP and KYN pathways, they are not considered in any study in this review yet may 723 724 serve as a moderating factor that perpetuates a negative feedback loop which contributes to chronicity or a risk for symptom relapse, notably in the postpartum period due to poor quality of sleep as a result of 725 726 child rearing responsibilities. Meaning, certain biochemical pathways may account for specific 727 depression symptoms and indicate subtypes of perinatal depression that can be leveraged to increase precision in detection and intervention. 728

In the context of PPD, these findings may indicate when dietary intake of tryptophan or 729 tryptophan uptake promoting foods are limited amid immune and inflammatory responses, competitor 730 731 amino acids are being prioritized for transport across the BBB and/or TRP may be shunted towards the 732 KYN pathway. Moreover, both pathways may result in decreased production of the neurotransmitter serotonin and explain the risk for and onset of PPD, and the level of risk would be further increased for 733 734 those with a genetic predisposition (i.e., genetic polymorphisms) or those experiencing the other 735 biopsychosocial or behavioral factors discussed in this review. Thus, future investigations are needed to further explore these prospective interactions as these interactions may serve as significant risk factors 736 737 of PPD that can be detected and intervened upon during pregnancy.

#### 738 Conclusion

The factors discussed in this review have been independently indicated as probable determinants 739 740 of PPD risk and onset. However, what is not evident in independent investigations but is demonstrated in this review is that various interactions among diverse determinants and TRP metabolism may provide 741 a deeper understanding of what contributes to the pathophysiology of perinatal depression or perinatal 742 depression risk. Future investigations are needed to address methodological issues in maternal mental 743 744 health science and care as well as explore these prospective interactions as these interactions hold potential to evolve as a PPD risk phenotype (observable characteristics). Such a phenotype can serve as 745 a robust foundation for the development of clinically efficient yet meaningful mechanisms for risk 746 747 detection and inform patient centered risk mitigation strategies. Further, the present review establishes the value of integrative approaches in the investigation of perinatal depression and suggests the 748 application of team science principles (e.g., collaboration, diverse expertise) may be particularly useful 749 750 to this area of inquiry to expedite the discovery of clinically relevant findings and strengthen scientific methods. 751

#### 752 Acknowledgments

Thank you to all the authors and participants for your contributions in progressing maternal mental
health science and care by either conducting or participating in the studies discussed in this review.

#### 755 **References**

Trost SL, Beauregard J, Chandra G, Nije F, Berry J, Harvey A, et al. Pregnancy-related deaths:
 Data from maternal mortality review committees in 36 US states, 2017–2019. 2022 Sep.

Dagher RK, Bruckheim HE, Colpe LJ, Edwards E, White DB. Perinatal depression: Challenges
 and opportunities. J Womens Health. 2021 Feb 1;30(2):154–9.

3. American Congress of Obstetricians and Gynecologists (ACOG) Committee. Screening for

761		perinatal depression. Committee Report. Washington (DC); 2015. Report No.: 757. Available
762		from: https://pubmed-ncbi-nlm-nih-gov.ezproxy.lib.utexas.edu/30629567/
763	4.	American Psychiatric Association (APA). Depressive disorders. In: Diagnostic and statistical
764		manual of mental disorders: DSM-5 (5th ed.). Arlington: American psychiatric publishing Inc.
765		2013.
766	5.	American Congress off Obstetricians and Gynecologists (ACOG). Opioid use and opioid use
767		disorder in pregnancy committee on obstetric practice American society of addiction medicine.
768		Report. 2021. Available from: http://www.integration.samhsa.gov/
769	6.	Admon LK, Dalton VK, Kolenic GE, Ettner SL, Tilea A, Haffajee RL, et al. Trends in suicidality
770		1 Year before and after birth among commercially insured childbearing individuals in the United
771		States, 2006-2017. JAMA Psychiatry. 2021 Feb 1;78(2):171-6.
772	7.	Campbell J, Matoff-Stepp S, Velez ML, Cox HH, Laughon K. Pregnancy-associated deaths from
773		homicide, suicide, and drug overdose: Review of research and the intersection with intimate
774		partner violence. J Womens Health. 2021 Feb 1;30(2):236-44.
775	8.	Texas Department of States Health Services (DSHS). The Role of opioid overdoses in confirmed
776		maternal deaths, 2012-2015. Report. 2017. Available from:
777		https://www.dshs.texas.gov/mch/DSHS-Maternal-Mortality-and-Morbidity-Presentations-and-
778		Publications/.asp
779	9.	Emerson MR, Mathews TL, Struwe L. Postpartum depression screening for new mothers at well
780		child visits. MCN Am J Matern Child Nurs. 2018;43(3):139–45.
781	10.	Curry SJ, Krist AH, Owens DK, Barry MJ, Caughey AB, Davidson KW, et al. Interventions to
782		prevent perinatal depression: US Preventive Services Task Force recommendation statement. Vol.

47

783	321, JAMA - Journal of the American Medical Association. American Medical Association; 2019
784	p. 580–7.

- 11. Bauman BL, Ko JY, Cox S, D'Angelo DV, Warner L, Folger S, et al. Vital signs: postpartum
- depressive symptoms and provider discussions about perinatal depression United States, 2018.
- 787 MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):575–81.
- Van Niel MS, Payne JL. Perinatal depression: A review. Cleve Clin J Med. 2020 May;87(5):273–
  7.

13. Yim IS, Tanner Stapleton LR, Guardino CM, Hahn-Holbrook J, Dunkel Schetter C. Biological and

- 791 psychosocial predictors of postpartum depression: Systematic review and call for integration.
- Annu Rev Clin Psychol. 2015 Mar 28;11(1):99–137.
- 14. Yonkers KA, Wisner KL, Stewart DE, Oberlander TF, Dell DL, Stotland N, et al. The
- management of depression during pregnancy: a report from the American Psychiatric Association
- and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry. 2009

796 Sep;31(5):403–13.

- 15. Hutchens BF, Kearney J. Risk factors for postpartum depression: An umbrella review. Vol. 65,
  Journal of Midwifery and Women's Health. John Wiley and Sons Inc.; 2020. p. 96–108.
- Biaggi A, Conroy S, Pawlby S, Pariante CM. Identifying the women at risk of antenatal anxiety
  and depression: A systematic review. J Affect Disord. 2016 Feb;191:62–77.
- 801 17. e Couto C, Martins Brancaglion MY, Alvim-Soares A, Moreira L, Garcia FD, Nicolato R, et al.
- 802 Postpartum depression: A systematic review of the genetics involved. World J Psychiatry.
- 803 2015;5(1):103.

804	18.	Yang YC, Schorpp K, Boen C, Johnson M, Harris KM. Socioeconomic status and biological risks
805		for health and illness across the life course. J Gerontol B Psychol Sci Soc Sci. 2020 Feb
806		14;75(3):613–24.

- Bor 19. Dell'Osso L, Carmassi C, Mucci F, Marazziti D. Depression, serotonin and tryptophan. Curr
  Pharm Des. 2016 Feb 15;22(8):949–54.
- 809 20. Beck CT. Predictors of Postpartum Depression. In: Nursing Research. Philadelphia: Wolters
  810 Kluwer; 2001. Vol. 50. p. 275-285.
- 811 21. Guintivano J, Manuck T, Meltzer-Brody S. Predictors of postpartum depression: A comprehensive
- review of the last decade of evidence. Vol. 61, Clinical Obstetrics and Gynecology. Lippincott

813 Williams and Wilkins; 2018. p. 591–603.

- 22. Dougherty DM, Richard DM, Dawes MA, Mathias CW, Acheson A, Hill-Kapturczak N. L-
- 815 Tryptophan: Basic metabolic functions, behavioral research and therapeutic indications. Vol. 2,
  816 International Journal of Tryptophan Research. 2009.
- 817 23. Groer M, Fuchs D, Duffy A, Louis-Jacques A, D'Agata A, Postolache TT. Associations among
  818 obesity, inflammation, and tryptophan catabolism in pregnancy. Biol Res Nurs. 2018 May
  819 1;20(3):284–91.
- 820 24. Miller AH, Raison CL. The role of inflammation in depression: From evolutionary imperative to

modern treatment target. Vol. 16, Nature Reviews Immunology. Nature Publishing Group; 2016.

- 822 p. 22–34.
- 823 25. Abu-Raya B, Michalski C, Sadarangani M, Lavoie PM. Maternal immunological adaptation during
  824 normal pregnancy. Vol. 11, Frontiers in Immunology. Frontiers Media S.A.; 2020.

825	26.	Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
826		2020 statement: An updated guideline for reporting systematic reviews. PLoS Med. 2021 Mar
827		29;18(3):e1003583.
828	27.	Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for
829		systematic reviews. Syst Rev. 2016 Dec 5;5(1):210.
830	28.	American Psychiatric Association (APA) [Internet]. APA Dictionary of Psychology. [cited 2023
831		June]. Available from: https://dictionary.apa.org/
832	29.	Healthy People 2030 [Internet]. Social Determinants of Health. [cited 2023 June]. Available from
833		https://health.gov/healthypeople/priority-areas/social-determinants-health
834	30.	Critical Appraisal Skills Programme (CASP) [Internet]. Cohort study, case-control study,
835		randomized control trial Checklist. 2018. [cited 2023 June]. Available from: https://casp-
836		uk.net/casp-tools-checklists/
837	31.	Downes MJ, Brennan ML, Williams HC, Dean RS. Development of a critical appraisal tool to
838		assess the quality of cross-sectional studies (AXIS). 2016. Available from:
839		http://dx.doi.org/10.1136/bmjopen-2016-011458
840	32.	Handley SL, Dunn TL, Waldron G, Baker JM. Tryptophan, cortisol and puerperal mood. British
841		Journal of Psychiatry. 1980 May 29;136(5):498-508.
842	33.	Achtyes E, Keaton SA, Smart L, Burmeister AR, Heilman PL, Krzyzanowski S, et al.
843		Inflammation and kynurenine pathway dysregulation in post-partum women with severe and
844		suicidal depression. Brain Behav Immun. 2020 Jan;83:239-47.
845	34.	Bailara K, Henry C, Lestage J, Launay J, Parrot F, Swendsen J, et al. Decreased brain tryptophan
846		availability as a partial determinant of post-partum blues. Psychoneuroendocrinology. 2006
847		Apr;31(3):407–13.

- 848 35. Chang JPC, Lin CY, Lin PY, Shih YH, Chiu TH, Ho M, et al. Polyunsaturated fatty acids and
- 849 inflammatory markers in major depressive episodes during pregnancy. Prog

850 Neuropsychopharmacol Biol Psychiatry. 2018 Jan;80:273–8.

- 36. Christian LM, Franco A, Glaser R, Iams JD. Depressive symptoms are associated with elevated
- serum proinflammatory cytokines among pregnant women. Brain Behav Immun. 2009

853 Aug;23(6):750–4.

- 854 37. Comasco E, Sylvén SM, Papadopoulos FC, Sundström-Poromaa I, Oreland L, Skalkidou A.
  855 Postpartum depression symptoms. Psychiatr Genet. 2011 Feb;21(1):19–28.
- Bissociation between vitamin B12 status and probable postpartum depression in Indian women.
  BMC Pregnancy Childbirth. 2021 Dec 17:21(1):146.
- 39. Fasching PA, Faschingbauer F, Goecke TW, Engel A, Häberle L, Seifert A, et al. Genetic variants
  in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy. J
- 861 Psychiatr Res. 2012 Sep;46(9):1109–17.
- 40. Finy MS, Christian LM. Pathways linking childhood abuse history and current socioeconomic
  status to inflammation during pregnancy. Brain Behav Immun. 2018 Nov;74:231–40.
- 41. Garman EC, Schneider M, Lund C. Perinatal depressive symptoms among low-income South
- African women at risk of depression: trajectories and predictors. BMC Pregnancy Childbirth. 2019
  Dec 14;19(1):202.
- 42. Kimmel M, Jin W, Xia K, Lun K, Azcarate-Peril A, Plantinga A, et al. Metabolite trajectories
- 868 across the perinatal period and mental health: A preliminary study of tryptophan-related
- 869 metabolites, bile acids and microbial composition. Behavioural Brain Research. 2022
- 870 Feb;418:113635.

871	43.	Lin YMJ	, Ko HC,	Chang FM	I, Yeh TL	, Sun HS. F	<b>Population-s</b>	pecific	functional	variant	of the

- 872 TPH2 gene 2755C>A polymorphism contributes risk association to major depression and anxiety
- in Chinese peripartum women. Arch Womens Ment Health. 2009 Dec 9;12(6):401–8.
- 44. Miller ES, Grobman WA, Culhane J, Adam E, Buss C, Entringer S, et al. Antenatal depression,
- psychotropic medication use, and inflammation among pregnant women. Arch Womens Ment
- Health. 2018 Dec 4;21(6):785–90.
- 45. Miyake Y, Tanaka K, Okubo H, Sasaki S, Arakawa M. Tryptophan intake is related to a lower

878 prevalence of depressive symptoms during pregnancy in Japan: baseline data from the Kyushu

879 Okinawa Maternal and Child Health Study. Eur J Nutr. 2022 Dec 27;61(8):4215–22.

- 46. Murakami K, Miyake Y, Sasaki S, Tanaka K, Yokoyama T, Ohya Y, et al. Dietary glycemic index
  and load and the risk of postpartum depression in Japan: The Osaka Maternal and Child Health
  Study. J Affect Disord. 2008 Sep;110(1–2):174–9.
- 47. Moses-Kolko EL, Wisner KL, Price JC, Berga SL, Drevets WC, Hanusa BH, et al. Serotonin 1A
  receptor reductions in postpartum depression: a positron emission tomography study. Fertil Steril.
  2008 Mar;89(3):685–92.
- 48. Nazzari S, Molteni M, Valtorta F, Comai S, Frigerio A. Prenatal IL-6 levels and activation of the
  tryptophan to kynurenine pathway are associated with depressive but not anxiety symptoms across
  the perinatal and the post-partum period in a low-risk sample. Brain Behav Immun. 2020
  Oct;89:175–83.
- 49. Rihua X, Haiyan X, Krewski D, Guoping H. Plasma concentrations of neurotransmitters and
- postpartum depression. Journal of Central South University Medical Sciences. 2018;43(3):274–81.

- 50. Robertson Blackmore E, Mittal M, Cai X, Moynihan JA, Matthieu MM, O'Connor TG. Lifetime
- 893 Exposure to Intimate Partner Violence and Proinflammatory Cytokine Levels Across the Perinatal

Period. J Womens Health. 2016 Oct;25(10):1004–13.

- 51. Ross KM, Miller G, Qadir S, Keenan-Devlin L, Leigh AKK, Borders A. Close relationship
- qualities and maternal peripheral inflammation during pregnancy. Psychoneuroendocrinology.

897 2017 Mar;77:252–60.

- Sha Q, Madaj Z, Keaton S, Escobar Galvis ML, Smart LA, Krzyzanowski S, et al. Cytokines and
  tryptophan metabolites can predict depressive symptoms in pregnancy. Transl Psychiatry. 2022
  Dec 1;12(1).
- 53. Tebeka S, Le Strat Y, Etain B, Ray M, Mullaert J, Dubertret C. Childhood trauma and perinatal
  depression. J Clin Psychiatry. 2021 Sep 7;82(5).
- 54. Teshigawara T, Mouri A, Kubo H, Nakamura Y, Shiino T, Okada T, et al. Changes in tryptophan
  metabolism during pregnancy and postpartum periods: Potential involvement in postpartum
  depressive symptoms. J Affect Disord. 2019 Aug 1;255:168–76.
- 55. Vargas-Terrones M, Barakat R, Santacruz B, Fernandez-Buhigas I, Mottola MF. Physical exercise
   programme during pregnancy decreases perinatal depression risk: a randomised controlled trial. Br
   J Sports Med. 2019 Mar;53(6):348–53.
- 56. Veen C, Myint AM, Burgerhout KM, Schwarz MJ, Schütze G, Kushner SA, et al. Tryptophan

pathway alterations in the postpartum period and in acute postpartum psychosis and depression. J
Affect Disord. 2016 Jan;189:298–305.

912 57. Venkatesh KK, Meeker JD, Cantonwine DE, McElrath TF, Ferguson KK. Association of antenatal

913 depression with oxidative stress and impact on spontaneous preterm birth. Journal of Perinatology.

914 2019 Apr 5;39(4):554–62.

915	58.	World Health Organization (WHO) [Internet]. Trends in maternal mortality 2000 to 2017:
916		Estimates by WHO, UNICEF, UNFPA, World Bank Group and the United Nations Population
917		Division. 2019. [cited 2023 June]. Available from: https://apps.who.int/iris/handle/10665/327596
918	59.	Texas Health and Human Services [Internet]. Revised - Texas Maternal Mortality and Morbidity
919		Review Committee and Department of State Health Services Joint Biennial Report. 2022. [cited
920		2023 June]. Available from: https://www.dshs.texas.gov/sites/default/files/legislative/2020-
921		Reports/DSHS-MMMRC-2020.pdf
922	60.	Centers for Disease Control and Prevention (CDC) [Internet]. Maternal deaths and mortality rates:
923		Each state, the District of Columbia, United States, 2018-2020. [cited 2023 June]. Available from:
924		https://www.cdc.gov/nchs/maternal-mortality/mmr-2018-2021-state-data.pdf
925	61.	Howell EA, Mora PA, Horowitz CR, Leventhal H. Racial and ethnic differences in factors
926		associated with early postpartum depressive symptoms. Vol. 105, Obstetrics and Gynecology.
927		2005. p. 1442–50.
928	62.	Centers for Disease Control and Prevention (CDC) [Internet]. Pregnancy mortality surveillance
929		system. 2022. [cited 2023 June]. Available from:
930		https://www.cdc.gov/reproductivehealth/maternal-mortality/pregnancy-mortality-surveillance-
931		system.htm
932	63.	Osterman J. K. M. Changes in primary and repeat cesarean delivery: United States 2016-2021.
933		Atlanta, Georgia; 2022 Jul.
934	64.	Valdes EG. Examining cesarean delivery rates by race: A population-based analysis using the
935		robson ten-group classification system. J Racial Ethn Health Disparities. 2021 Aug 17;8(4):844-
936		51.

937	65.	Pope CJ, Mazmanian D. Breastfeeding and postpartum depression: An overview and
938		methodological recommendations for future research. Depress Res Treat. 2016:1–9.
939	66.	Miller MJ, Kennedy AD, Eckhart AD, Burrage LC, Wulff JE, Miller LAD, et al. Untargeted
940		metabolomic analysis for the clinical screening of inborn errors of metabolism. J Inherit Metab
941		Dis. 2015 Nov 15;38(6):1029–39.
942	67.	Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: Development of the 10-item
943		Edinburgh Postnatal Depression scale. British Journal of Psychiatry. 1987;150(JUNE):782-6.
944	68.	Levis B, Negeri Z, Sun Y, Benedetti A, Thombs BD. Accuracy of the Edinburgh Postnatal
945		Depression Scale (EPDS) for screening to detect major depression among pregnant and postpartum
946		women: systematic review and meta-analysis of individual participant data. BMJ. 2020 Nov
947		11;m4022.
948	69.	Qiu X, Wu Y, Sun Y, Levis B, Tian J, Boruff JT, et al. Individual participant data meta-analysis to
949		compare EPDS accuracy to detect major depression with and without the self-harm item. Sci Rep.
950		2023 Mar 10;13(1):4026.
951	70.	Snaith RP, Constantopoulos AA, Jardine MY, McGuffin P. A clinical scale for the self-assessment
952		of irritability. British Journal of Psychiatry. 1978 Feb 29;132(2):164-71.
953	71.	Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983
954		Jun.
955	72.	Bedford A, Foulds GA, Sheffield BF. A New Personal Disturbance Scale (DSSI/sAD). British
956		Journal of Social and Clinical Psychology. 1976 Nov;15(4):387-94.
957	73.	Wright ML, Podnar J, Longoria KD, Nguyen TC, Lim S, Garcia S, Wylie D. Comparison of
958		commercial DNA extraction kits for whole metagenome sequencing of human oral, vaginal, and

- 959 rectal microbiome samples. bioRxiv. 2023 Feb 2:2023-02. Available from: https://pubmed-ncbi960 nlm-nih-gov.ezproxy.lib.utexas.edu/36778319/
- 961 74. DeMyer MK. Plasma tryptophan and five other amino acids in depressed and normal subjects.
  962 Arch Gen Psychiatry. 1981 Jun 1;38(6):642.
- 963 75. Savitz J. The kynurenine pathway: a finger in every pie. Mol Psychiatry. 2020 Jan 12;25(1):131–
  964 47.
- 76. Cho HJ, Savitz J, Dantzer R, Teague TK, Drevets WC, Irwin MR. Sleep disturbance and
  kynurenine metabolism in depression. J Psychosom Res. 2017 Aug:99:1–7.
- 967 77. Opmeer EM, Kortekaas R, van Tol MJ, van der Wee NJA, Woudstra S, van Buchem MA, et al.
- 968 Influence of COMT val158met genotype on the depressed brain during emotional processing and
  969 working memory. PLoS One. 2013 Sep 12;8(9):e73290.
- 970 78. Dickinson D, Elvevåg B. Genes, cognition and brain through a COMT lens. Neuroscience. 2009
  971 Nov;164(1):72–87.
- 972 79. Sheikh HI, Kryski KR, Smith HJ, Dougherty LR, Klein DN, Bufferd SJ, et al. Catechol-O-
- 973 methyltransferase gene val158met polymorphism and depressive symptoms during early
- 974 childhood. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics. 2013
  975 Apr;162(3):245–52.
- 80. Naoi M, Riederer P, Maruyama W. Modulation of monoamine oxidase (MAO) expression in
  neuropsychiatric disorders: genetic and environmental factors involved in type A MAO
  expression. J Neural Transm. 2016 Feb 22;123(2):91–106.
- 81. Liu Z, Huang L, Luo XJ, Wu L, Li M. MAOA Variants and Genetic Susceptibility to Major
  Psychiatric Disorders. Mol Neurobiol. 2016 Sep;53(7):4319–27.

981	82.	Liu ZL, Wang XQ, Liu M fan, Ye B juan. Meta-analysis of association between TPH2 single
982		nucleotide poiymorphism and depression. Neurosci Biobehav Rev. 2022 Mar;134:104517.
983	83.	Gao J, Pan Z, Jiao Z, Li F, Zhao G, Wei Q, et al. TPH2 Gene polymorphisms and major depression
984		– A meta-analysis. PLoS One. 2012 May 31;7(5):e36721.
985	84.	Rogne T, Tielemans MJ, Chong MFF, Yajnik CS, Krishnaveni G V., Poston L, et al. Associations
986		of maternal vitamin B12 concentration in pregnancy with the risks of preterm birth and low birth
987		weight: A systematic review and meta-analysis of individual participant data. Am J Epidemiol.
988		2017 Jan 20.
989	85.	Finkelstein JL, Layden AJ, Stover PJ. Vitamin B-12 and perinatal health. Advances in Nutrition.
990		2015 Sep;6(5):552-63.
991	86.	National Institutes of Health (NIH) Office of Dietary Supplements (ODS) [Internet]. Vitamin B12
992		Fact Sheet for Health Professionals. 2022. [cited 2023 June]. Available from:
993		https://ods.od.nih.gov/factsheets/VitaminB12-HealthProfessional/
994	87.	Hsu MC, Tung CY, Chen HE. Omega-3 polyunsaturated fatty acid supplementation in prevention
995		and treatment of maternal depression: Putative mechanism and recommendation. J Affect Disord.
996		2018 Oct;238:47–61.
997	88.	Markun S, Gravestock I, Jäger L, Rosemann T, Pichierri G, Burgstaller JM. Effects of vitamin B12
998		supplementation on cognitive function, depressive symptoms, and fatigue: A systematic review,
999		meta-analysis, and meta-regression. Nutrients. 2021 Mar 12;13(3):923.
1000	89.	Wolters M, von der Haar A, Baalmann AK, Wellbrock M, Heise TL, Rach S. Effects of n-3
1001		Polyunsaturated Fatty Acid Supplementation in the Prevention and Treatment of Depressive

1002 Disorders—A Systematic Review and Meta-Analysis. Nutrients. 2021 Mar 25;13(4):1070.

- 1003 90. Liao Y, Xie B, Zhang H, He Q, Guo L, Subramanieapillai M, et al. Efficacy of omega-3 PUFAs in
  1004 depression: A meta-analysis. Transl Psychiatry. 2019 Aug 5;9(1):190.
- 91. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review
  focused on risks and controversies. Acta Psychiatr Scand. 2013 Feb;127(2):94–114.
- 92. Goodman JH. Women's attitudes, preferences, and perceived barriers to treatment for perinatal
  depression. Birth. 2009 Mar;36(1):60–9.
- 1009 93. Labaka A, Goñi-Balentziaga O, Lebeña A, Pérez-Tejada J. Biological sex differences in
  1010 depression: A systematic review. Biol Res Nurs. 2018 Jul 14:20(4):383–92.
- 1011 94. Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. P5-HT1A receptors in mood and anxiety:
- recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology (Berl). 2014
   Feb 12;231(4):623–36.
- 1014 95. Wang D, Wu J, Zhu P, Xie H, Lu L, Bai W, et al. Tryptophan-rich diet ameliorates chronic
- 1015 unpredictable mild stress induced depression- and anxiety-like behavior in mice: The potential
- 1016 involvement of gut-brain axis. Food Research International. 2022 Jul;157:111289.
- 96. Correia AS, Vale N. Tryptophan metabolism in depression: A narrative review with a focus on
  serotonin and kynurenine pathways. Int J Mol Sci. 2022 Jul 31:23(15):8493.
- 97. Posmontier B. Functional status outcomes in mothers with and without postpartum depression. J
  Midwifery Womens Health. 2008;53(4):310–8.
- 1021 98. Blount AJ, Adams CR, Anderson-Berry AL, Hanson C, Schneider K, Pendyala G.
- 1022 Biopsychosocial factors during the perinatal period: Risks, preventative factors, and implications
- 1023 for healthcare professionals. Vol. 18, International Journal of Environmental Research and Public
- 1024 Health. MDPI AG; 2021.

- 1025 99. Yang K, Wu J, Chen X. Risk factors of perinatal depression in women: a systematic review and
  1026 meta-analysis. BMC Psychiatry. 2022 Dec 1;22(1).
- 1027 100. Fox B, Brod M. Pregnancy and delivery complications cost the United States billions in health care
- expenses, lost productivity, and social support services. 2021 Nov.
- 1029 101. Feeding America [Internet]. The impact of the coronavirus on local food insecurity in 2020 &
- 1030 2021. Report. 2021 Mar. [cited 2023 June]. Available from:
- 1031 https://www.feedingamerica.org/research/coronavirus-hunger-research
- 1032 102. Mehedint MG, Gulledge A. Nutritional impact on cognitive development. In: Reference Module in
   Biomedical Sciences. Elsevier; 2014.
- 1034 103. Pawluski JL, Li M, Lonstein JS. Serotonin and motherhood: From molecules to mood. Front
   1035 Neuroendocrinol. 2019 Apr;53:100742.
- 1036 104. Markus CR. Dietary Amino Acids and Brain Serotonin Function; Implications for Stress-Related
   1037 Affective Changes. Neuromolecular Med. 2008 Dec 31;10(4):247–58.
- 1038 105. Gao K, Pi Y, Mu CL, Farzi A, Liu Z, Zhu WY. Increasing carbohydrate availability in the hindgut
- 1039 promotes hypothalamic neurotransmitter synthesis: aromatic amino acids linking the microbiota-
- 1040 brain axis. J Neurochem. 2019 Jun;149(5):641–59.
- 1041 106. Huang Y, Lin X, Lin S. Neuropeptide Y and Metabolism Syndrome: An Update on Perspectives of
- 1042 Clinical Therapeutic Intervention Strategies. Front Cell Dev Biol. 2021 Jul 9;9.
- 1043 107. Beck B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity.
- 1044 Philosophical Transactions of the Royal Society B: Biological Sciences. 2006 Jul
- 1045 29;361(1471):1159–85.
- 1046 108. Neumeister A. Tryptophan depletion, serotonin, and depression: where do we stand?

1047 Psychopharmacol Bull. 2003;37(4):99–115.

## **1048** Supporting information

- 1049 **S1 Table. Description of risk of bias considerations.** Author<sup>2</sup> indicates the study was a secondary
- 1050 analysis. ®Study reported race and/or ethnicity.
- 1051 S1 Checklist. PRISMA 2020 Checklist.

#### **1052** Financial disclosure statement

- 1053 KDL is supported by the National Institute of Nursing Research of the National Institutes of Health
- 1054 (T32NR019035). The content is solely the responsibility of the authors and does not necessarily
- 1055 represent the official views of the National Institutes of Health.






Fig1



Dubligations

Texas (n = 3)







<sup>a</sup> Miller et al. (2018)	в	Р		$\bigcirc$	$\bigcirc$
Murakami et al. (2008)	Bh	PN			$\bigcirc$
Rihua et al. (2018)	в	PP	$\bigcirc$		
Veen et al. (2016)	в	PP	$\bigcirc$		$\bigcirc$
Bailara et al. (2006)	в	PP	$\bigcirc$		$\bigcirc$
Tebeka et al. (2021)	s	PP	$\bigcirc$		
<sup>a</sup> Venkatesh et al. (2019)	в	Р	$\bigcirc$		$\bigcirc$

# Fig3